The Interplay Between Hypoxia (HIF) and Inflammation (NF-B) in Colon Cancer by Bartnicka, Kamila Joanna
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
The Interplay Between Hypoxia (HIF) and Inflammation (NF-￿B) in Colon
Cancer
Bartnicka, Kamila Joanna
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-107750
Originally published at:
Bartnicka, Kamila Joanna. The Interplay Between Hypoxia (HIF) and Inflammation (NF-￿B) in Colon
Cancer. 2014, University of Zurich, Faculty of Science.
The Interplay Between Hypoxia (HIF) and 
Inflammation (NF-B) in Colon Cancer 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
Kamila Joanna Bartnicka 
aus 
Polen 
Promotionskomitee: 
Prof. Dr. Roland H. Wenger (Vorsitz) 
Prof. Dr. David Hoogewijs (Leitung der Dissertation) 
Prof. Dr. Dr. Michael O. Hottiger 
PD. Dr. Lubor Borsig 
Zürich, 2014           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of contents: 
1. Abbreviation list              1 
2. Zusammenfassung              6 
3. Summary               9 
4. Introduction             11 
4.1. Cancer            11 
4.1.1. What is tumour           11 
4.1.2. Benign and malignant tumours        11 
4.1.3. Carcinogenesis           12 
4.1.4. Hallmarks of cancer          13 
4.2. Hypoxia            18 
4.2.1. Introduction to hypoxia and its assessment in tumours     18 
4.2.2. Sensing and response to hypoxia on the systemic and cellular    20 
level             
4.2.3. Hypoxia/HIF as powerful players in cancer       24 
4.3. Inflammation           30 
4.3.1. Inflammation as a mechanism of response to pathogenic insult    30 
4.3.2. Cells and their products involved in inflammtory response    31 
4.3.3. Inflammation on the cellular level – NF-B, the master     33  
regulator of inflammatory responses      
4.3.4. Toll-like receptor signalling         37 
4.3.5. TLR4 pathway           40 
4.3.6. The role of NF-B in the intestinal epithelium              44 
4.3.7. Inflammation, NF-B and cancer        45 
4.3.7.1. Immune cells in carcinogenesis       47 
4.4. Colorectal cancer, a model to study the interplay between     51  
hypoxic and inflammatory pathways       
4.5. Connections between hypoxia/HIF and inflammation/NF-B     54 
5. Aims of the thesis            58 
6. Results             59 
6.1. Manuscript – Hypoxia attenuates the inflammatory response in    59 
colon cancer cells 
ABSTRACT            59 
INTRODUCTION           61   
RESULTS            62   
DISCUSSION           66   
MATERIALS AND METHODS         69   
FIGURE LEGENDS          72   
FIGURES AND TABLES          75
      
6.2. Additional unpublished data         84    
RESULTS            84 
DISCUSSION           86 
MATERIALS AND METHODS         88 
FIGURE LEGENDS          88 
 
 
FIGURES            90 
6.3. Personal contribution          93 
7. Conclusions             94 
8. References             99 
9. Acknowledgments          112 
10. Curriculum vitae          113 
 
 
  
Abbreviation list 
1 
 
1. Abbreviation list  
AhR   aryl hydrocarbon receptor 
Ang   angiopoietin 
AOM   azoxymethane 
AP   activator protein 
APC adenomatous polyposis coli or anaphase promoting complex or 
antigen presenting cell 
ARNT   aryl hydrocarbon receptor nuclear translocator 
ATM   ataxia telangiectasia mutated 
ATP   adenosine triphosphate 
BAFF   B cell activating factor of the TNF family 
BCL   B-cell lymphoma 
bHLH   basic helix-loop-helix  
BNIP   BCL-2/adenovirus E1B 19 kDa interacting protein 
CA   carbonic anhydrase 
CAC   colitis-associated cancer 
cAMP   cyclic adenosine monophosphate 
CBP   CREB-binding protein 
CCL   chemokine (C-C motif) ligand 
CD   cluster of differentiation or Crohn`s disease 
CDK   cyclin-dependent kinase  
cFLIP   cellular FLICE-like inhibitory protein 
cIAP   cellular inhibitor of apoptosis 
CIN   chromosomal instability 
CK   casein kinase 
COX   cyclooxygenase 
CPG   central pattern generator 
CRC   colorectal cancer 
CREB   cAMP responsive element binding protein 
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CXCL   chemokine (C-X-C motif) ligand 
CXCR   chemokine (C-X-C motif) receptor 
DC   dendritic cells 
DMOG  dimethyloxalylglycine 
DSB   double-strand break 
dsRNA  double-stranded RNA 
DSS   dextran sodium sulfate 
DUB   deubiquitinase 
ECM   extracellular matrix 
EGF   epidermal growth factor 
EGLN   egl nine homolog 
EMT   epithelial-to-mesenchymal transition 
EPAS   endothelial PAS domain-containing protein 
FAP   familial adenomatous polyposis 
FIH   factor inhibiting HIF 
GLUT   glucose transporter 
GM-CSF  granulocyte/macrophage colony-stimulating factor 
Gro   growth-regulated protein 
HBS   HIF binding site 
HIF   hypoxia inducible factor 
HIV   human immunodeficiency virus 
HNPCC  hereditary non-polyposis colon cancer 
HPV   human papillomavirus 
HRE   hypoxia response element 
IBD    inflammatory bowel disease 
ICAM   intercellular adhesion molecule 
IFN   interferon 
IGF    insulin-like growth factor 
IKK   inhibitor of kappa B kinase 
IL   interleukin 
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iNOS   inducible nitric oxide synthase 
IRAK   interleukin-1 receptor associated kinase 
IRF   interferon regulatory factor 
ITF   intestinal trefoil factor 
IB   inhibitor of kappa B 
LBP   LPS binding protein 
LDHA   lactate dehydrogenase A 
LPS   lipopolysaccharide 
LRR   leucine-rich repeat 
MAL   MyD88-adapter-like 
MAPK  mitogen-activated protein kinase 
MCP   monocyte chemotactic protein 
M-CSF  macrophage colony-stimulating factor  
MDR   multidrug resistance 
MDSC  myeloid-derived suppressor cells 
MMP   matrix metalloproteinase 
MSH   MutS protein homolog 
MSI or MIN  microsatellite instability 
MyD88  myeloid differentiation primary response protein 88 
NEMO  NF-B essential modulator  
NES   nuclear export signal 
NF-B  nuclear factor kappa B 
NIK   NF-B-inducing kinase 
NK   natural killer 
NLS   nuclear localization signal 
NO   nitric oxide 
ODD   oxygen-dependent degradation  
OTU   ovarian tumour    
OTUB   OTU domain, ubiquitin aldehyde binding 
PAS   Per-Arnt-Sim 
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PDGF   platelet-derived growth factor 
PDK   pyruvate dehydrogenase kinase 
Per   period circadian protein 
PET   positron emission tomography  
PGK   phosphoglycerate kinase 
PHD   prolyl-4-hydroxylase domain 
PI3K    phosphoinositide 3-kinase 
PKC   protein kinase C 
PMN   polymorphonuclear 
PTGS   prostaglandin-endoperoxide synthase 
RHD   Rel homology domain 
RIP   receptor-interacting protein kinase 
ROS    reactive oxygen species 
SDF   stromal cell-derived factor 
shRNA  short hairpin RNA 
SIGIRR  single immunoglobin IL-1R-related 
SIM   single-minded protein 
siRNA  small interfering RNA 
SKP   S-phase kinase-associated protein 
ssRNA  single-stranded RNA 
STAT   signal transducer and activator of transcription 
TAB   TGF-beta activated kinase 1 (MAP3K7) binding protein 
TAD   transactivation domain 
TAK1   TGF-beta activated kinase 1 
TAM   tumour-associated macrophage 
TAN   tumour-associated neutrophil 
TANK   TRAF family member-associated NF-B activator 
TBK   TANK-binding kinase 
TGF   transforming growth factor 
Tie   tunica interna endothelial cell kinase 
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TIR   Toll/interleukin-1 receptor 
TIRAP  TIR domain-containing adapter protein 
TLR   Toll-like receptor 
TNBS   2,4,6-trinitrobenzene sulfonic acid 
TNF   tumour necrosis factor 
TNFAIP  tumour necrosis factor alpha-induced protein 
TNFR   tumour necrosis factor receptor 
TRADD  TNFR1-associated death domain protein 
TRAF   tumour necrosis factor receptor-associated factor 
TRAM  TRIF-related adaptor molecule 
TRIF Toll/interleukin-1 receptor domain-containing adapter protein 
inducing interferon beta 
UBC   ubiquitin conjugating enzyme 
UC   ulcerative colitis 
uPA   urokinase-type plasminogen activator 
uPAR   urokinase-type plasminogen activator receptor 
VCAM  vascular cell adhesion molecule  
VEGF   vascular endothelial growth factor 
VHL   von Hippel-Lindau 
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2. Zusammenfassung 
Das kolorektale Karzinom ist die zweithäufigste Krebserkrankungen bei Frauen und 
die dritthäufigste bei Männern. Hypoxie und Entzündung sind untrennbare Merkmale 
von Krebserkrankungen und beeinflussen dieselben kritischen Prozesse der 
Krebsentwicklung wie z.B. das Überleben der Zellen, Zellinvasion, Angiogenese, 
Metastasierung und Therapieresistenz. Hypoxie und Entzündung sind beides 
Merkmale von Krebserkrankungen, einschliesslich dieses Krebstyps. Die 
Hauptakteure der zellulären Anpassung an Hypoxie sind die Hypoxie-induzierbaren 
Faktoren 1 und 2 (HIF-1 und HIF-2). Beide setzen sich aus einer sauerstoff-
empfindlichen Untereinheit (HIF-1 oder -2 und dem konstitutiv exprimierten 
Bindungspartner HIF zusammen. HIF-1 wird universell exprimiert. HIF-2 zeigt 
hingegen eine Zelltyp-spezifische Expression. Unter normalen Sauerstoff-
bedingungen werden die HIF- Untereinheiten nach der Hydroxylierung durch Prolyl-
4-Hydroxylase (PHD)-Proteine rasch durch das Proteasom abgebaut. Hypoxie führt 
durch die Inhibierung der PHD-Enzyme zur Stabilisierung von HIF-. Infolgedessen 
bilden HIF- und HIF ein funktionelles Heterodimer, welches die Zielgene aktiviert. 
Der primär für die Entzündungsreaktion verantwortliche Transkriptionsfaktor NF-B 
besteht aus zwei Untereinheiten, vor allem p65/RelA und p50. Unter unstimulierten 
Bedingungen wird NF-B von inhibierenden Proteinen (hauptsächlich IB) im 
Zytoplasma zurückgehalten. Eine proinflammatorische Stimulation führt zur 
Phosphorylierung und Abbau von IB. Durch Translokation gelangt NF-B dann in 
den Zellkern und aktiviert dort die Zielgene. Aktivierung von HIF-1 wie auch NF-B 
werden dabei mit einer schlechteren Prognose für die Patienten in Verbindung 
gebracht. Darüber hinaus besteht eine gut bekannte Assoziation zwischen einer 
chronisch-entzündlichen Darmerkrankung und einem erhöhten Malignitätsrisiko. Im 
Allgemeinen wird davon ausgegangen, dass es auf mehreren Ebenen zu 
Interaktionen zwischen dem Hypoxie- und dem Entzündungssignalweg kommt, wie 
etwa bei der direkten transkriptionellen Aktivierung von HIF-1 durch NF-B oder der 
Hypoxie-vermittelten Aktivierung von NF-B. Das Ziel dieser Arbeit bestand daher 
darin, eine umfassende Analyse der Relevanz dieser beiden Signalwege beim 
kolorektalen Karzinom, wie auch eine Untersuchung eines möglichen Wechselspiels 
zwischen diesen beiden Signalwegen in diesem Krebsmodell vorzunehmen. Die 
Zusammenfassung 
 
7 
 
Hypoxieexposition von MC-38 Zellen führt zur Stabilisierung des HIF-1Proteins und 
zur Aktivierung der bekannten HIF-Zielgene Glut1, Ca9 und Phd3 auf mRNA-Ebene. 
MC-38 Zellen zeigen eine robuste Antwort des Transkriptionsfaktors NF-B auf einen 
entzündungsfördernden Stimulus. Die Behandlung dieser Zellen mit LPS führt zur 
Translokation von NF-B in den Zellkern und zur Aktivierung der Zielgene Tnfa, Il6 
und Cox2. Dieser Effekt der LPS-Stimulierung wird noch verstärkt, wenn die Zellen in 
3D (in hängenden Tropfen) kultiviert werden. Der HIF Signalweg (das HIF-1 
Transkript und der Proteinspiegel, wie auch die Glut1, Ca9 und Phd3 Genexpression) 
wird durch die proinflammatorische Stimulation der MC-38 Zellen mit LPS nicht 
beeinflusst, während der NF-B Signalweg aktiviert wird. Auch in mehreren 
getesteten kolorektalen Krebszelllinien konnte keine transkriptionelle Regulation der 
HIF-1 mRNA nach einer Behandlung mit LPS festgestellt werden. Ferner reagieren 
MC-38 Zellen unter Hypoxie in dem sie den HIF Signalweg aktivieren, was aber nicht 
zu einer stärkeren NF-B Aktivität führte. Interessanterweise ist die hypoxische 
Induktion sowohl des HIF-1 Proteins wie auch der GLUT-1, CAIX und PHD3 
Zielgene unverändert, wenn die basale NF-B Aktivität fehlt, was durch einen Knock-
down von p65/RelA in MC-38 Zellen gezeigt werden konnte. Auch zeigt die LPS 
Behandlung von MC-38 Zellen mit einem HIF-1 Knock-down, dass die basale HIF-
1 Expression irrelevant für die nukleäre Translokation von NF-B, wie auch für die 
Expression von TNF- und IL-6 ist. Eine RNA Sequenzierungsanalyse der 
Genregulation unter verschiedenen Sauerstoffbedingungen und/oder LPS 
Behandlung zeigte eine profunde gegenseitige Abhängigkeit der beiden Signalwege. 
58% der unter Hypoxie heraufregulierten Gene benötigen für ihre Induktion HIF-1, 
wie auch NF-B, während nur ungefähr 11% der Gene, die durch eine LPS 
Behandlung heraufreguliert werden, von beiden Transkriptionsfaktoren abhängig 
sind. Ein anderes unerwartetes Resultat der kombinierten Hypoxie- und LPS 
Exposition war die Hypoxie vermittelte Abschwächung der Antwort der MC-38 Zellen 
auf die LPS Behandlung. Die Gesamtanzahl der Gene, welche durch eine LPS-
Behandlung induziert werden, verringerte sich in der Hypoxie um etwa 50%, 
verglichen mit den ebenfalls LPS behandelten Zellen in Normoxie. Die 
nachfolgenden Experimente zeigten, dass die Hypoxie die LPS-stimulierte 
IBAbnahme und die Translokation von NF-B in den Zellkern beeinträchtigt. 
Dieser Effekt ist von HIF-1 unabhängig. Der höhere IB Menge erklärt wenigstens 
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teilweise die verminderte Entzündungsantwort in MC-38 Zellen unter Hypoxie. 
Schliesslich zeigte die RNA Sequenzierung eine HIF-1Abhängigkeit der Inhibition 
der LPS Induzierbarkeit von verschiedenen gut bekannten NF-B Zielgenen (Ccl20, 
Cxcl5, Csf2 und Tnfa). Diese Resultate wurden durch unabhängige Validierung 
mittels RT-qPCR bestätigt. Die oben genannten Gene sind in der Rekrutierung und 
Aktivierung von Leukozyten involviert. Deshalb ist es notwendig eine Analyse dieses 
Effektes von HIF-1 (sowie auch der neu identifizierten HIF-1 regulierten 
Entzündungsmediatoren) durchzuführen, um einen Einblick in die in vivo Relevanz 
von HIF-1 als gestaltender Faktor für die Entzündungsreaktion in diesem Krebstyp zu 
erhalten.  
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3. Summary 
Colorectal cancer is the second most common malignancy in women and the third in 
men. Hypoxia and inflammation are two inseparable hallmarks of cancer influencing 
the same crucial processes in carcinogenesis, including cell survival, invasion, 
angiogenesis, metastasis and resistance to therapy. The main players involved in the 
cellular response to hypoxia are hypoxia-inducible factor-1 and -2 (HIF-1 and HIF-2) 
composed of the oxygen-labile subunit HIF-1or HIF-2, respectively, and their 
constitutively expressed common interaction partner HIF. Whereas HIF-1 is 
expressed ubiquitously, HIF-2 displays a cell type-specific expression pattern. In 
normal oxygen conditions HIF- subunits are rapidly degraded by proteasomes. 
Normoxic disassembly of HIF- is associated with the activity of prolyl-4-hydroxylase 
domain (PHD) enzymes. Hypoxia leads to the stabilization of HIF- by inhibiting PHD 
enzyme activity. HIF- subunits form functional heterodimers with HIF 
subsequently activating HIF target genes. The main transcription factor involved in 
the classically activated inflammatory response is the NF-B heterodimer composed 
of p65/RelA and p50 subunits. Under unstimulated conditions, NF-B is retained in 
the cytoplasm by interacting with inhibitory proteins (mainly IB). Proinflammatory 
stimulation of the cell results in the phosphorylation and degradation of IB. 
Liberated NF-B dimers translocate to the nucleus and activate target genes. 
Activation of both, HIF-1 and NF-B has been linked to poorer colorectal carcinoma 
patient prognosis. Furthermore, there is a well established association between 
inflammatory bowel disease and increased risk of developing colorectal cancer. 
There are several levels of established interactions between hypoxic and 
inflammatory pathways, including direct transcriptional activation of HIF-1 by NF-B, 
and hypoxia-mediated activation of NF-B. Therefore, the aim of this work was a 
comprehensive analysis of the relevance of both pathways in colon cancer cells as 
well as the study of their possible interplay in this cancer model. Hypoxic exposure of 
MC-38 cells resulted in the stabilization of HIF-1 protein and activation of its 
classical target genes Glut1, Ca9 and Phd3. MC-38 cells also displayed a robust 
response of the transcription factor NF-B to proinflammatory stimulation. Treatment 
of MC-38 cells with LPS led to nuclear NF-B translocation and activation of its target 
  Summary 
 
10 
 
genes Tnfa, Il6 and Cox2. The effect of LPS stimulation of MC-38 is further enhanced 
in cells grown in 3D hanging drop culture conditions. The HIF pathway (HIF-1 
transcript and protein levels, as well as Glut1, Ca9 and Phd3 gene expression) is 
unaltered under conditions of proinflammatory treatment with LPS in MC-38 cells, 
despite activation of NF-B signalling. In line, no transcriptional regulation of HIF-1 
mRNA upon treatment with LPS could be observed in a panel of human colon cancer 
cell lines tested. Furthermore, although MC-38 cells respond to hypoxia by 
upregulating the HIF pathway, hypoxic treatment does not lead to an increase in NF-
B levels or activity. Interestingly, the hypoxic induction of the HIF-1 protein, as well 
as GLUT-1, CAIX and PHD3 transcripts is independent of NF-B, as studied in MC-
38 cells with p65/RelA knock-down. Similarly, basal HIF-1 expression was irrelevant 
for NF-B nuclear translocation and for the expression of TNF- and IL-6 following 
the LPS treatment, as addressed in MC-38 cells with HIF-1 knock-down. RNA deep 
sequencing was performed to gain a further insight into complexity of combined 
hypoxic and proinflammatory treatment. Exposure of MC-38 cell to hypoxia and/or 
LPS revealed profound mutual dependence of both pathways. An unexpectedly high 
proportion of 58% of hypoxically upregulated genes required both HIF-1 and NF-B 
for their induction, whereas LPS-mediated upregulation of only about 11% of genes 
needed both transcription factors. Another unexpected result of combined hypoxic 
and inflammatory treatment was the hypoxia-mediated attenuation of molecular 
response to LPS. The total number of genes induced by the combined treatment with 
LPS and hypoxia was decreased by about 50% compared to LPS alone. The follow-
up experiments showed that hypoxia impairs LPS-stimulated IB levels decrease 
leading to attenuated nuclear translocation of NF-B, an effect that was independent 
of HIF-1. Inhibiting the decrease in IB at least in part explains the diminished 
inflammatory response in MC-38 cells in hypoxia. Finally, RNA deep sequencing, 
confirmed by independent RT-qPCR validation, revealed an increase in the LPS-
inducibility of several well known NF-B target genes (Ccl20, Cxcl5, Csf2 and Tnfa) 
in the absence of HIF-1. Those genes are known to be involved in the recruitment 
and activation of leukocytes. Future analysis of the effect of HIF-1 (and each of newly 
identified HIF-1-regulated inflammatory mediators) aiming at investigating the in vivo 
relevance of HIF-1 as a factor shaping the inflammatory component in this type of 
malignancy is required.  
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4. Introduction 
4.1. Cancer 
14.1 million new cancer cases were diagnosed in 2012 and cancer accounted for 8.2 
million deaths worldwide in the same year. Among them, tumours of lung, liver, 
stomach, colorectum and prostate are major cause of cancer-related deaths in men, 
and of breast, lung, colorectum, cervix uteri and stomach in women (1).  
Research on cancer has it beginnings in the late XIX century when Johannes 
Mueller, a German microscopist, described the cellular nature of cancer. This 
discovery started the long study on the differences between normal and cancerous 
tissues (2). 
4.1.1. What is tumour 
It is crucial to distinguish non-pathologic conditions, resulting from increased demand 
applied on a given organ or its hormonal stimulation, leading to hypertrophy 
(increased size of the cells, e.g. muscle cells in athletes) or hyperplasia (increased 
number of cells, e.g. of endometrium in female monthly cycle) from neoplasia (the 
formation of tumour). Hyperthrophy and hyperplasia are stimulus-dependent and 
cease when that cause/stimulus is withdrawn (2). In turn, the commonly cited 
definition of neoplasm (tumour), formulated by the British oncologist R.A. Willis, says: 
“A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is 
uncoordinated with that of the normal tissues, and persists in the same excessive 
manner after cessation of the stimulus which evoked the change” (3). 
4.1.2. Benign and malignant tumours 
Tumours are divided into benign and malignant (malignancies or cancers). Benign 
tumours, in general, remain well differentiated and are characterized by slow growth 
(4). Benign neoplasms may be harmful e.g. by local pressure or obstruction, 
however, they grow locally, do not invade surrounding tissue and do not spread to 
distal sites of the body. In contrast, cancers infiltrate the underlying mesenchyme and 
form metastases in other organs. Furthermore, malignancies range from well 
differentiated to anaplastic (lacking differentiation) and their growth rate can be slow 
or rapid. Cancer typically arises from epithelium (carcinomas), however, it may also 
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originate from mesenchyme (sarcoma), hematopietic cells (leukemias), lymphoid 
tissue (lymphomas) or from the neural system (2, 4).  
4.1.3. Carcinogenesis 
The major groups of genes involved in cancer are oncogenes (activated 
protooncogenes) which stimulate cell proliferation, tumour suppressor genes which 
inhibit proliferation, as well as genes that regulate programmed cell death 
(apoptosis). A separate class of genes, whose altered expression influences cancer 
development, are genes involved in DNA damage repair. This group contributes to 
the altered expression of oncogenes, tumour supressors and apoptosis regulators by 
affecting the organism ability to repair nonlethal DNA damage and therefore 
predisposing to DNA mutations (4). Furthermore an emerging group of 
carcinogenesis regulators are epigenetic modifiers of DNA and histones, chromatin 
remodelers and noncoding RNAs (5-10).  
Stages of carcinogenesis encompass tumour initiation, promotion and progression. 
During the initiation phase a normal cell acquires first irreversible alteration in the 
expression of an oncogene or a tumour suppressor as a result of DNA mutation (11). 
Such alternations in the genome occur mainly somatically. Rarely, however, a 
mutated gene can be inherited as it is the case in early childhood retinoblastoma 
(cancer of retina) with congenital mutational loss of one of the two Retinoblastoma 
(Rb) tumour suppressor loci. Inheritance of one dysfunctional allele greatly increases 
the chance of developing malignancy upon somatic loss of its other functional copy 
(12-14). Of note, recent studies have drawn more attention towards the role of 
epigenetic silencing of tumour suppressors in cancer initiation (11).  
The promotion stage results in propagation of initiated clones, increasing the number 
of affected cells and thereby also the chance that one of them acquires further 
alterations in gene expression and undergoes malignant transformation (11). Tumour 
promoting agents/processes stimulate the proliferation of preneoplastic cells or inhibit 
their apoptosis. A classical well studied example of a tumour promoter is 12-O-
tetradecanoylphorbol-13-acetate (TPA) which activates the protein kinase C (PKC) 
pathway by intercalating to the cell membrane and mimicking diacylglycerol (15). The 
cancer promoting effect of phorbol ester results from downstream activation of the 
transcription factors activator protein (AP) - 1 and nuclear factor-kappa B (NF-B) 
(16-19). Among clonally expanding cells, acquisition of further alterations leads over 
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time to the development of a malignant phenotype and entry into the progression 
phase (11).  
4.1.4. Hallmarks of cancer 
The characteristic traits of cancer cells (or cancer) encompass sustained proliferative 
signalling, avoidance of growth suppression, resistance to proapoptotic signalling, 
limitless replicative potential, promoting angiogenesis, invasion of surrounding 
tissues, formation of distal metastases and evasion of immunosurveillance. Individual 
cancer acquires those hallmarks at different stages and via distinct mechanisms. 
However, there are two superior characteristics of cancer development, which enable 
all of the above mentioned other alterations, and those are genomic instability and 
the presence of inflammatory component in the tumour microenvironment (20). 
Improper genome fidelity maintenance results from dysfunction of DNA damage 
detectors and activators of the repair systems, components of DNA repair 
machineries or proteins detoxifying mutagens before the DNA damage occurs. 
Furthemore, compromised surveillance systems, which in normal conditions direct 
genetically damaged cells to senescence or apoptosis, with a central role of 
“guardian of the genome” TP53 (p53), are also responsible for genomic instability. 
Increased rate of mutation acquisition gives rise to development of other cancer 
hallmarks (20). Genomic instability is characteristic for almost all cancers, including 
malignancies associated with hereditary conditions and sporadic tumours. Consistent 
with the “mutator hypothesis” (on occurrence of a genomic instability at early stage of 
carcinogenesis, which in turn increases mutation rate and therefore cancer 
development), there are several types of cancer resulting from inherited mutations in 
DNA repair mechanisms. For instance in the hereditary non-polyposis colon cancer 
(HNPCC), also known as Lynch syndrome, mutations of DNA mismatch repair genes 
lead to alterations in the number of short repeated nucleotide sequences, called 
microsatellite instability (MSI or MIN). As a consequence, frame-shift mutations in 
other genes occur. On the other hand, the main form of genomic instability in 
sporadic cancers, chromosomal instability (CIN), is proposed to be mediated by 
oncogen-induced DNA replication stress (stalling and collapse of the replication 
forks), resulting in induction of DNA double-strand breaks (DSBs). Furthermore, 
under these circumstances, the cells with loss of tumour supressor p53, which is a 
main regulator of growth arrest, senescence or apoptosis in response to DNA 
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damage, or ataxia telangiectasia mutated (ATM), which encodes a kinase activating 
p53 upon DNA damage, gain a further selection advantage in growing tumours (21, 
22).  
The other “superior” hallmark of cancer is ongoing inflammation. It has long been 
known that solid tumours are infiltrated by inflammatory cells owing Rudolf Virchow`s 
first observations of this phenomenon already in the 19th century (23). Inflammatory 
processes may result from cancer development (and e.g. oncogenic activation) or 
precede the development of a tumour (24). Malignant microenvironment contains an 
inflammatory component whose presence is usually associated with worse, but in 
some cases with better cancer patient prognosis, suggesting different 
priming/polarization of inflammation in cancer development (25-30).  
As introduced above, cancers possess the abilities to evade immune surveillance, 
which allows tumour to coexist with the host immune system. One of further 
mechanisms of how cancers avoid recognition by the host`s immunity is loss or 
downregulation of major histocompatibility complex (MHC) class I. Decreased 
expression of MHC class I renders cancer cells invisible for the cytotoxic T 
lymphocytes (31). Furthermore, increased release of lactate in the tumour 
microenvironment inhibits the action of natural killer (NK) cells which represent 
another important players in the host`s tumour surveillance. Elevated concentration 
of lactate, which is associated with high glycolytic activity of cancer, directly 
attenuates the cytolytic function of NK cells as well as recruits myeloid-derived 
suppressor cells (MDSC) which further inhibit NK cells (32).  
Well established features of cancer are sustained proliferative (associated with 
activation of oncogenes) and dysfunctional growth limiting signalling (related to loss 
of tumour suppressor genes). Increased proliferation rate in cancer can result from 
an autocrine/paracrine stimulation of the cancerous cell with overexpressed, self-
produced or tumour-associated stroma cell-derived growth factors. Alternatively, 
elevation of the expression levels of a receptor recognizing growth factor available in 
a limited concentration in the tumour microenvironment can give a growth advantage 
to cancer cells. Similarly, mutational change in the structure of such receptor or the 
downstream components of its signalling pathway, resulting in their constitutive 
activation may be a mechanism of increasing proliferation rate in cancer. On the 
other hand, loss of the negative feedback upon stimulation of a growth factor 
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pathway also gives rise to excessive cell division (20). For instance, insulin growth 
factors (IGFs), which signal via phosphoinositide 3-kinase (PI3K), are commonly 
overexpressed, whereas negative regulators of this pathway are often lost in cancer 
cells (e.g. loss of PTEN tumour suppressor) (33, 34). The other extensively studied 
examples of tumour suppressors associated with common human malignancies are 
RB (retinoblastoma) and TP53 (or p53) proteins. RB functions mainly via inhibition of 
the E2F transcription factor family, therefore preventing entry into S-phase of the cell 
cycle. Phosphorylation of RB by cyclin-dependent kinases (CDKs) leads to its 
inactivation, release of E2F and cell cycle progression. However, the tumour 
suppressor role of RB spans beyond interaction with E2F transcription factors. 
Retinoblastoma participates in the regulation of cell cycle arrest by interaction with S-
phase kinase-associated protein 2 (Skp2) and/or anaphase promoting complex 
(APC) to stabilize CDK inhibitor p27kip1 (35). In turn, p53 responds to cellular 
stresses and abnormalities, and therefore is required for prevention of cell cycle 
progression upon recognition of cellular alterations including DNA damage, incorrect 
mitotic spindle assembly, activation of oncogenes, oxidative stress or insufficient 
levels of nucleotides (36-43). Activated p53 regulates mainly expression of the genes 
responsible for growth arrest, DNA repair, senescence and/or apoptosis (44).  
Another well known property of cancer cells is the ability to avoid apoptosis. Among 
the regulators of programmed cell death are two groups. The first responses to 
intracellular stresses including DNA damage, cytokine deprivation and oncogene 
activation, whereas the other receives and processes the extracellular signals such 
as Fas ligand (FasL), TNF-related apoptosis-inducing ligand (TRAIL) and tumour 
necrosis factor (TNF- which activate their cognate death receptors. The ultimate 
event leading to cell disassembly is the activation of caspase 9 and 8 in response to 
activation of intra- and extracellular pathways, respectively (45).  
The intrinsic (or mitochondrial) pathway triggering apoptosis has been especially 
widely implicated in cancer pathogenesis. The execution of apoptosis in the intrinsic 
pathway depends mainly on the balance between pro- and antiapoptotic protein 
subfamilies of the BCL-2 family. BCL-2, BCL-X and BCL-W are examples of 
antiapoptotic subfamily members which bind and sequester proapoptotic regulators. 
Bax and Bak belong to proapoptotic BCL-2 molecular players permeabilizing the 
outer mitochondrial membrane. Another group of proapoptotic regulators of the 
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intrinsic apoptosis pathway are “BH3-only proteins” (e.g. p53 targets Puma and 
Noxa) which share the BCL-2 Homology region 3 (BH3) with BCL-2 family members. 
“BH3-only proteins” serve as specific damage sensors and direct antagonists of the 
antiapoptotic regulators. In turn, Bax and Bak seem to be activated following two 
possible models. In the direct model, activation of the proapoptotic proteins is 
mediated by binding “BH3-only proteins”, whereas in the indirect model, “BH3-only 
proteins” displace proapoptotic BCL-2 members from their antiapoptotic relatives. 
Activation of the Bax and Bak results in the release of cytochrom c, followed by the 
downstream recruitment of the cascade of caspases which perform cellular 
disassembly (46). The most common mechanisms of avoidance of apoptosis in 
cancer is loss of p53 tumour suppressor, increased expression of antiapoptotic 
regulators and/or survival factors or decreased expression of proapoptotic mediators 
(20).  
Acquisition of limitless proliferative potential by cancer cells is another characteristic 
of tumour progression. Normal cells have limited number of cell cycles that can be 
accomplished before they enter replicative senescent due to progressive telomeric 
DNA truncation after each replication of the genome. Cancer cells preserve the 
activity of telomerase (the enzyme responsible for elongation of telomeres) which 
enables unlimited number of divisions (47).    
Another feature of cancer which is crucial for tumour growth and metastasis is 
formation of new blood vessels. As the tumour diameter reaches up to 1-2 mm, 
hypoxia triggers an “angiogenic switch” to allow restoring blood supply, therefore 
oxygen and nutrient delivery (48). Angiogenesis is a process in which new blood 
vessels in hypoxic tumours are formed from existing established vasculature,  
associated with induction of endothelial cell proliferation and migration. The 
prototypical mediator of angiogenesis is vascular endothelial growth factor (VEGF). 
Its regulation in hypoxia and association with increased capillary density in human 
cancer samples was shown already over 20 years ago (49). Shortly afterwards, it 
became clear that hypoxia activates hypoxia inducible factors (HIFs), subsequently 
increasing the expression of VEGF (50). Angiogenesis is also closely related to 
inflammatory processes. Experiments employing stable knock-down of HIF-1 
(oxygen-sensitive subunit of HIF-1) in a model of colon cancer xenograft growth in 
mice indicated sustained angiogenesis in the absence of functional HIF pathway. The 
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induction of proangiogenic interleukin 8 (IL-8) expression was shown to promote 
angiogenesis in HIF-1knock-down-derived tumours. Hypoxic HIF-1knock-down 
cells displayed upregulation of IL-8 as a result of activation of the major regulator of 
inflammatory responses nuclear factor – kappa B (NF-B) (51). Of further importance 
for the angiogenic processes in cancer is the recruitment of myeloid cells to tumour 
microenvironment (52). Strong support for this notion are findings on the positive 
correlation between the number of tumor-associated macrophages (TAMs) and 
microvascular density observed in human cancers (53-55). Furthermore, clodronate 
liposomes-mediated depletion of monocytes resulted in decreased angiogenesis in a 
model of Lewis lung carcinoma xenograft growth in mice (56). TAMs are known to be 
a potent source of multiple angiogenesis stimulating factors including VEGF, IL-8, 
platelet derived growth factor  (PDGF) and matrix metalloproteinases (MMPs) (52).  
As mentioned above, cancer cells acquire the ability to invade surrounding tissue and 
form distal metastases. The model of cancer cell metastasis embraces: local invasion 
of surrounding tissue, invasion of the blood or lymphatic vessels (intravasation), 
survival in the bloodstream, extravasation at the distal site, survival at that site and its 
colonization (formation of the macroscopic secondary tumour) (57). The key 
adhesion molecule involved in preserving the integrity of epithelial tissue is E-
cadherin. Decreased expression of E-cadherin is a well established event in 
epithelial-to-mesenchymal transition (EMT), an initial step in metastatic process 
cascade (58). Loss of E-cadherin expression occurs frequently in human cancers and 
is associated with disease progression (59-61).  
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4.2. Hypoxia 
4.2.1. Introduction to hypoxia and its assessment in tumours 
Hypoxia, defined as insufficient oxygen supply, elicits adaptive changes, promotes 
survival or leads to apoptosis of affected cells. However, oxygen availability has been 
shown to be involved in the regulation of physiological conditions such as embryonic 
development, inflammation, wound healing and adaptation to high altitude, as well as 
pathological conditions including ischemic diseases and cancer (62).  
Physiologically normal values of tissue oxygen partial pressure (normoxic conditions) 
range from 14.4 to 64.8 mm Hg. In some cases, however, e.g. in the thymus, kidney 
medulla and bone marrow these values drop even below 7.2 mm Hg due to unusual 
blood vessel networks at these sites (63). It has been shown in all human malignant 
tumours studied that the level of oxygenation is lower in cancerous tissue compared 
to the median value of its tissue of origin (64). Hypoxia is associated with poorer 
prognosis in patients with different tumours including best studied malignancies of 
cervix, head and neck and soft tissue sarcoma (65-67). To obtain this knowledge 
direct oxygen-sensitive microsensor electrodes (Eppendorf pO2 histogrphy) were 
applied in cancer patients. Nevertheless, this method has its disadvantages such as 
invasiveness and limitation of the access of a needle probe only to certain tumours 
(68). Polarographic sensors have further drawback, oxygen is being consumed 
during the measurements, and this precludes their use for measuring the 
oxygenation over time (69). Successors of polarographic electrodes became 
fluorescence-based fiber-optic probes, sensors which are usually made out of 
fluorescent dye ruthenium chloride held in a polymer matrix. The fluorescence light 
emission by those probes is quenched in an oxygen-dependent manner and remains 
inversely proportional to oxygen partial pressure. An important advantage of optical 
sensors over polarographic probes is no oxygen consumption during the 
measurements (69).   
For the detection of insufficient oxygen availability in tumours several endogenous 
hypoxia-induced proteins e.g. hypoxia inducible factor-1 (HIF-1) and its target 
genes carbonic anhydrase 9 (CA-IX) and glucose transporter 1 (GLUT-1), can be 
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applied in tissue sample analysis. However, the expression of HIF-1, CA-IX and 
GLUT-1 has sometimes been reported to show a pattern which clearly does not 
correlate to the direct tumour oxygen measurement results. There are several 
possible explanations for that including suboptimal immunohistochemistry protocols 
and the influence of tumour microenvironment on expression of those markers (68). 
For example, it has been shown that HIF-1 stabilization can be a result of acidosis, 
whereas glucose deprivation may abrogate hypoxic CA-IX induction or stimulate 
induction of GLUT-1 (70-72). In addition, overexpression of HIF and its target genes 
may occur due to oncogene/tumour supressor pathways dysfunction (68).    
Among hypoxia imaging techniques, exogenous markers e.g. 2-nitroimidazole 
derivatives such as 1-[(2-hydroxy-3-piperidinyl) propyl]-2-nitroimidazole hydrochloride 
(pimonidazole) or 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) 
acetamide (EF5) can also be used in humans upon their injection preceding tumour 
biopsy/resection (73-76). Those compounds have been shown to be reduced and 
strongly interact with cellular macromolecules when the oxygen partial pressure 
drops below 10 mm Hg. Formation of such adducts in hypoxic conditions may be 
detected by specific antibodies (76). However, oxygen-independent staining of 
pimonidazole adducts was also reported, suggesting that hypoxia-independent 
effects may influence the results obtained with exogenous hypoxia markers (69).  
Non-invasive in vivo tumour hypoxia assessment techniques include imaging with 
positron emission tomography (PET) and magnetic resonance imaging (MRI). 
Radiolabelled 2-nitroimidazoles such as [18F] Fluoromisonidazole (FMISO), [18F] 
Fluoroazomycin-arabinose (FAZA) and [18F] EF5, and other oxygen-sensitive probes 
e.g. [60Cu] or [64Cu] Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) 
have been developed and applied for hypoxia imaging by PET in preclinical and 
clinical studies (77). MRI techniques, which do not directly measure oxygenation, 
provide indirect information on hypoxia in tumours. This estimation is possible by 
measuring the fluctuations of magnetic resonance, which reflects the concentration of 
deoxyhemoglobin, vascular blood flow, vascular blood volume, or the presence of 
oxygen in tissue. In particular, blood oxygenation level-dependent (BOLD) MRI relies 
on the measurement of ratio of erythrocyte content of deoxyhaemoglobin (having 
paramagnetic properties) to oxyhaemoglobin (which is diamagnetic) (78).  
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Although numerous approaches to evaluate hypoxia in tumours have been 
developed none of them has found widespread clinical application yet.    
4.2.2. Sensing and response to hypoxia on the systemic and cellular level  
Neurons within medulla oblongata are responsible for producing rhythmic signals to 
stimulate respiratory muscles in a manner which does not depend on awareness. 
The exact site where neurons coordinating respiratory rhythm in normal conditions 
are located, so called central pattern generator (CPG), remains unknown. However, 
multiple neurons located in medulla, pons and other brainstem regions stimulate 
specific phases of the respiratory cycle (respiratory-related neurons, RRNs) (79).  
The most important tonic drive signals of CPG come from central and peripheral 
chemoreceptors which monitor the partial pressures of O2 and CO2, as well as pH. 
The peripheral chemoreceptors are situated in the carotid and aortic bodies. Both 
types are sensitive mainly to drop in arterial blood PO2. Of note, an increase in blood 
PCO2 as well as lowering of pH makes them more sensitive to decreased oxygen 
levels. Central chemoreceptors are located on the “brain” side of the blood-brain 
barrier. Those receptors sense the increase in arterial PCO2 and a decrease in 
cerebrospinal fluid pH, although the latter more slowly. Peripheral and central 
chemoreceptors deliver the tonic drive to CPG in parallel to their function in feedback 
regulation of the respiratory output (depth and frequency of ventilation) to stabilize 
blood values with regard to PO2, PCO2 and pH. Decreased PO2, increased PCO2 or 
lowered pH cause an increase in ventilation, aiming at acute raising blood PO2, 
decreasing PCO2 and elevating pH, to restore their correct values (79).  
Kidney is another organ responsible for monitoring systemic arterial blood 
oxygenation. Decreased blood oxygen content is detected by renal erythropoietin 
(EPO)-producing and oxygen sensing (REPOS) cells located along the 
corticomedullary oxygen gradient in the juxtamedullary cortex. Decreased 
oxygenation of the REPOSs leads to their proliferation and production of EPO. Next, 
endocrine secretion of EPO stimulates the erythropoiesis in bone marrow, resulting in 
counteracting the decreased oxygen blood content by the increase in blood oxygen 
transport capacity (80).   
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On the cellular level the main players involved in response to hypoxia in higher 
metazoans are HIF-1, HIF-2 and HIF-3, composed of the oxygen-dependent subunit 
HIF-1-2 or -3, respectively, and their constitutively expressed interaction partner 
aryl hydrocarbon receptor nuclear translocator - ARNT (or HIF (81). The HIF 
system was discovered already over 30 years ago, in the context of binding to a 18 
bp element in the 3` enhancer of EPO gene by a nuclear factor induced in hypoxia in 
Hep3B cells (82). HIF-1 is ubiquitously expressed, whereas HIF-2(also known as 
endothelial PAS domain-containing protein 1, EPAS1), which is a close relative of 
HIF-1 (both proteins share 48% of sequence homology), is expressed in a cell type-
specific manner. HIF-2expression is restricted to endothelium, stromal cells of 
brain, kidney and pancreas, parenchymal and stromal cells of the heart, as well as in 
parenchyma of liver and intestine (83-85). HIF-3 is less well characterized. 
However, it has been shown to be expressed in humans in at least seven splice 
variants, and appears to modulate the HIF-1- and HIF-2-mediated transcriptional 
response in hypoxia (86).   
HIF-1 and HIF-2 contain several distinct functional domains including: basic helix-
loop-helix (bHLH) and PAS (which are responsible for dimerization and DNA 
binding), oxygen-dependent degradation (ODD) domain (required for degradation by 
the ubiquitin-proteasome pathway) and two transactivation domains (NTAD and 
CTAD) (63). 
In normal oxygen conditions, prolyl-4-hydroxylase domain-1 (PHD1), PHD2 and 
PHD3 (also known as EGLN2, 1 and 3, respectively) hydroxylate two proline residues 
(402 and 564, and 405 and 531, in human HIF-1 and HIF-2respectively) in the 
ODD domain of HIF- marking it for interaction with ubiquitin ligase E3 von Hippel-
Lindau (VHL) tumour suppressor, and subsequent proteasomal degradation (87-91). 
PHD2 knock-out in mice leads to embryonic lethality between days 12.5 and 14.5 
due to severe placenta and heart malformation (92). Interestingly, knock-outs of 
PHD1 or PHD3 do not lead to any apparent phenotype, however, the outcome of a 
double PHD1 and PHD3 knock-out is moderate erythrocytosis (92, 93). Of note, a 
fourth prolyl-4-hydroxylase domain protein, endoplasmatic reticulum transmembrane 
PHD4 was shown to hydroxylate HIF- in vitro (94). PHD4 knock-out phenotype in 
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mice is characterized by mild kidney defect with minor late-onset proteinuria, and eye 
abnormalities observed in aging mice (95).  
Hydroxylation of the asparaginyl residues Asn803 and Asn851, in human HIF-1 and 
HIF-2, respectively, by the factor inhibiting HIF (FIH), prevents binding of the 
transcriptional coactivators p300/CBP, and therefore inhibits HIF activity in normoxia 
(96). Mice lacking FIH largely do not differ from the wild type animals regarding 
classical aspects of HIF functions, e.g. vascularization, erythropoiesis or 
development, however, they display lower body weight, increased rate of metabolism 
and hyperventilation, as well as are resistant to high-fat-diet-induced gain of weigh 
and hepatic steatosis (97). 
The activity of PHD and FIH enzymes is inhibited in hypoxia, therefore HIF- 
subunits can rapidly accumulate and interact with HIF and p300/CBP to activate the 
transcription of target genes (63). An overview of the oxygen-dependent regulation of 
HIF-1 is shown in Figure 1. The importance of HIFs is underscored by the HIF-1 
knock-out mouse embryo phenotype of severe cardiac and vascular malformations 
and lethality by day E10.5 (98). Similarly, lack of HIF-1 leads to a defective 
vascularization of the yolk sack and/or the embryonic part of the placenta, and death 
of the embryo by the E10.5 day (99, 100). In addition HIF-1 deficiency results in a 
decreased number of hematopoietic progenitors of the yolk sac (101). On the other 
hand, the results of global HIF-2 deletion remain model-dependent. In one study, 
knock-out embryos displayed severe vascular defects in the yolk sac, and died 
between days E9.5 and E12.5 (102). In another work, lack of HIF-2resulted in fatal 
respiratory distress syndrome (RDS) in neonatal animals, which was associated with 
insufficient surfactant production due to decreased VEGF expression (103). Finally, a 
third group showed, that mice lacking HIF-2 died by day E16.5 of heart failure (104). 
HIFs bind to the minimal consensus HIF binding site (HBS) CGTG within a hypoxia 
response element (HRE). However, based on the analysis of 107 known HBSs in 70 
well characterized HIF target genes, it was found, that the closest adjacent 
nucleotides occur also with nonrandom frequency e.g. A is present in the -1 position 
and C in the +5 position, in more than 75% and over 40% of all known HBSs, 
respectively (62). Furthermore, Chromatin Immunoprecipitation-sequencing (ChIP-
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seq) analysis of over 400 HBSs revealed further sequence preferences such as for T 
in the -2 position and CAC motif between +13 and +15 positions (105). 
 
        
Figure 1 Oxygen-dependent regulation of HIF-1In normal oxygen conditions PHD1/2/3 mediate 
Pro402 and 564 (in human) hydroxylation in ODD domain of HIF-1, enabling its interaction with VHL 
and proteasomal degradation. On the other hand, FIH-mediated hydroxylation of Asn803 prevents 
HIF-1from interacting with p300/CBP transcriptional co-activator. In the conditions of decreased 
oxygen partial pressure, PHD 1/2/3 and FIH enzymes are inhibited, therefore HIF-1is stabilized, and 
binds HIF-1 and p300/CBP to transcriptionally regulate the expression of target genes (schematic 
organization of HIF subunits – modified from Schofield C.J., Ratcliffe P.J., 2004 (106)). 
The HRE is defined as the minimal cis-regulatory element required for hypoxic 
induction of gene transcription. The presence of a HBS motif in a DNA sequence is 
mandatory but insufficient for hypoxia-mediated gene regulation. Binding of other 
transcription factors (not only hypoxia-inducible) leads to amplification of hypoxic 
response or confers tissue-specificity of hypoxia-targeted genes. For instance, 
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transcriptional activation of lactate dehydrogenase A (LDHA) requires ATF-1 and 
CREB-1 in addition to HIF-1, whereas AP-1 transcription factor cooperates with HIF-1 
to activate the expression of vascular endothelial growth factor (VEGF) (62). Several 
tandemly arrayed HBS may also function as a complete HRE as it is the case for the 
transferrin (TF) gene, several glycolytic enzymes and glucose transporter-1 (GLUT-1) 
(62). 
4.2.3. Hypoxia/HIF as powerful players in cancer 
The presence of hypoxic cells in human tumours was described for the first time in 
1955 by Thomlinson and Gray. All investigated by them tumours of more than 200 
m radius, which approximately corresponds to the tissue oxygen diffusion limit, 
displayed necrotic cores. This observation suggested that the necrotic cells belong to 
the region of no oxygen availability, and that the adjacent cells must be exposed to 
decreased oxygen conditions. Together with the preceding work by Gray, which 
showed that low oxygen availability limits cell death after exposure to ionizing 
radiation, these findings strongly implied, that the hypoxic cells in tumour compose 
the mayor obstacle in effective cancer radiotherapy (107).  
A growing tumour is a dynamic structure with the cycles of local hypoxia and 
reoxygenation, while initially the distance to the nearest blood vessel increases 
resulting in hypoxia, and subsequently the blood flow is restored in the process of 
angiogenesis. Implications of periods of insufficient oxygen supply in cancer are 
manifold. As mentioned above one of the many important consequences of hypoxia 
is increased resistance to anticancer treatment. Interestingly, until 1972 there had 
been no explanation why multiple doses treatment is more efficient in tumour 
eradication than one single high dose of radiation. Ultimately, the work of Kallmann 
describing reoxygenation following irradiation of hypoxic tumours suggested, that the 
exposure to fractionated treatment may be beneficial due to normalization of oxygen 
conditions in initially hypoxic cancer sites (108).  
Among underlying mechanisms of hypoxia-mediated anticancer therapy resistance is 
the oxygen-mediated fixation of the unpaired electrons of free radicals induced by 
radiation. Efficient killing of normoxic mammalian cells requires 2.5 - 3 times lower 
dose of radiation than the same procedure performed in decreased oxygen 
conditions. On the other hand, hypoxic cells are the most difficult to target with 
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anticancer drugs due to their remote location with regard to blood vessels and 
decreased proliferation rate (64).  
Another aspect of hypoxia in cancer is the induction of profound molecular programs 
associated with expression of hypoxia inducible factors (HIFs), which influence the 
development and progression of a malignancy, as well as the treatment efficiency. 
HIF target genes are involved in glycolysis, cellular proliferation, survival or 
apoptosis, angiogenesis, invasion, metastasis and other processes, which will be 
described in more detail below. 
90 years ago Otto Warburg found, that thin slices of tumours ex vivo were 
characterized by increased glucose uptake and lactate production even in aerobic 
conditions. This phenomenon is called Warburg effect or aerobic glycolysis. The 
cause of increased glycolysis rate in aerobic conditions in cancers is partially the 
dysregulated expression of oncogenes/tumour supressors, however, this effect is 
strongly fueled by hypoxia- or nonhypoxic pathways-mediated stabilization of HIF-1 
(109). HIF targets are involved in regulation of glucose uptake (e.g. GLUT-1 and -3), 
glycolysis (e.g. lactate dehydrogenase A - LDHA, phosphoglycerate kinase 1 - PGK1, 
aldolase A and enolase 1), as well as inhibition of oxidative phosphorylation e.g. 
pyruvate dehydrogenase kinase 1 (PDK1) (110-115). Additionally, another well 
established HIF target gene CA-IX participates in normalization of the decreased 
intracellular pH (resulting from excessive lactate production) giving the cancer cells 
survival advantage in hypoxic and acidic microenvironment (116, 117).  
As a master of adaptation to hypoxic conditions HIF increases local blood flow to 
compensate for decreased oxygen concentrations in the blood. An increase in nitric 
oxide (NO) which is a major regulator of vasodilation and product of inducible nitric 
oxide synthase, iNOS (also known as NOS2) leads to widening of vessels and thus 
increased blood perfusion of a hypoxic region (118). The product of another HIF-
target gene cyclooxygenase-2 (COX-2), also known as prostaglandin-endoperoxide 
synthase 2 (PTGS2), leads to the synthesis of prostaglandin E2 (PGE2) which has 
similar regulatory effect on the vasculature like NO (119, 120).  
HIF is also a major orchestrator of angiogenesis, a process in which new blood 
vessels are created via sprouting of existing ones. The examples of well known HIF 
target genes involved in this process are the main regulators of endothelial 
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recruitment and proliferation, vascular endothelial growth factor (VEGF) and its 
receptors VEGFR1/R2 (50, 121, 122). Angiopoietin 2 (Ang-2) and TEK receptor 
tyrosine kinase (also known as tunica interna endothelial cell kinase, Tie-2) represent 
another examples of angiogenesis regulatory proteins under the control of HIF (85, 
123). Hypoxia-inducible Ang-2 is a natural antagonist of Ang-1, whose signalling via 
Tie-2 receptor mediates maturation and stabilization of the vessels. However, the 
action of Ang-2 destabilizes existing vessels and promotes their sprouting by 
disruption of the connection between endothelial and periendothelial cells, enhancing 
at the same time the effect of VEGF (124). Another HIF target PDGF- stimulates 
recruitment of pericytes that are required for the stabilization of the new tumour 
vasculature (125, 126). Matrix metalloproteinases 2 and 9 (MMP2 and 9), which were 
found to be directly transcriptionally targeted by HIF, play an important role in tumour 
angiogenesis, enabling endothelial cells to migrate through surrounding tissue and 
invade the tumour mass, among other functions (127-131). Similarly, urokinase-type 
plasminogen activator receptor (uPAR), also known as plasminogen activator, 
urokinase receptor (PLAUR), which is a regulator of plasminogen activation system 
(mediating tissue proteolysis), was shown to be regulated in a HIF-dependent 
manner (132). uPAR was shown to be required for the degradation of extracellular 
matrix in front of the leading edge of migrating endothelial cell (133). Moreover, 
products of iNOS and COX-2 are also proangiogenic factors, which upregulate the 
expression of VEGF (134-137). Furthermore, hypoxia leads to HIF-dependent 
upregulation of interleukin 8 (IL-8), which is a known angiogenesis modulator 
involved in endothelium survival and proliferation, as well as secretion of MMP2 and 
MMP9, therefore contributing to formation of the new vessels (138, 139). It has also 
recently been shown, that HIF-1 induces the recruitment of different populations of 
bone marrow-derived CD45+ myeloid cells (vascular modulators, which are not 
incorporated to the vasculature) as well as endothelial and pericyte precursor cells, 
which promote vasculature growth in glioblastoma. This action of HIF-1 is at least 
partially dependent on the expression of chemokine ligand CXCL12, also known as 
stromal cell-derived factor 1 (SDF-1) (140).  
An important role of HIF in cancer is regulation of cell survival/ apoptosis and 
proliferation. For instance, insulin-like growth factor 2 (IGF-2) and transforming 
growth factor  (TGF), which are implicated in cellular proliferation, are HIF-1-
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regulated genes (127, 141).  However, HIF-1 was shown to functionally counteract c-
Myc thereby derepressing p21 (CDK-interacting protein 1, CIP1) and inhibiting cell 
cycle progression in colon carcinoma cells (142). In turn, HIF-2 promoted the 
transcriptional activity of c-Myc stimulating cell cycle progression in renal cell 
carcinoma (RCC), NIH3T3, HEK293 and embryonic epithelial cells (143). Of note, 
chronic hypoxia may result in acquisition of proapoptotic phenotype via BCL-
2/adenovirus E1B 19 kDa interacting protein 3, BNIP3 (also known as NIP3) which is 
a proapoptotic protein induced in a HIF-dependent manner (144, 145). On the other 
hand, COX-2/prostaglandin E2 may play a role in cell survival and/or proliferation for 
instance by recruiting PI3K/AKT, mitogen-activated protein kinase (MAPK), cyclic 
adenosine monophosphate/protein kinase A (cAMP/PKA) and epidermal growth 
factor receptor (EGFR) signalling pathways in colon cancer cells (146).    
Among HIF target genes critically involved in carcinogenesis is lysyl oxidase (LOX), a 
gene required and sufficient to repress E-cadherin expression and promote epithelial-
to-mesenchymal transition (EMT), which is necessary for cancer invasion and 
metastasis (147, 148). A related role has been shown for other genes regulated by 
HIF, snail family zinc finger 1, SNAI1 (also known as Snail) and zinc finger E-box 
binding homeobox 2, ZEB2 (also known as SIP1), both acting as repressors of E-
cadherin expression (149). HIF target genes have further roles in the development of 
proinvasive and prometastatic phenotype. For instance, HIF-1 overexpression-
mediated invasiveness of colon cancer cells was blocked by neutralization of uPAR 
(127). Expression of uPAR was also implicated in the (angio)invasiveness of 
pancreatic and liver cancer cells (150). Degradation of extracellular matrix elicited by 
MMP2 and 9 further contributes to HIF-mediated invasion and metastasis by 
facilitating breakdown of epithelial basal membrane and underlying tissue, as well as 
intravasation by tumour cells (130, 151). Other HIF target genes such as chemokine 
receptor CXCR4 and its ligand CXCL12/SDF1 have a well established function in 
stimulating proliferation and homing of cancer cells to distal sites of the body (152-
156).  
Hypoxia contributes also to the genomic instability in cancer cells. For instance, 
transcriptional repression of MSH2 and MSH6 (DNA mismatch repair system 
components) in hypoxia, is dependent on HIF-1-mediated displacement of activator 
c-Myc from binding to Sp1 transcription factor, and concurrent hypoxic attenuation of 
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p53 MSH2 and MSH6 promoter DNA binding (157). In turn, NO (product of iNOS) 
may induce DNA damage or inhibit DNA repair systems mediating mutagenesis 
(158). 
The classical stimulus activating HIF- is hypoxia leading to the inhibition of PHD/FIH 
enzymes (63). Hypoxia occurs in solid cancers which outgrew the oxygen diffusion 
limit and have not yet developed intrinsic vasculature or the newly formed vessels 
have improper/leaking architecture. However, constitutively high levels of HIF are 
very common in cancers e.g. due to activation of oncogenes or loss of tumour 
suppressor genes (159).  
Almost 70% of examined cancer types displayed upregulated expression of HIF-1 
compared to their surrounding tissue. Among malignancies with dysregulated HIF-1 
expression were common human cancers such as colon, breast, gastric, lung, skin, 
ovarian, pancreatic and prostate carcinoma (160).  
Clinical investigations showed the association between increased HIF-1 expression 
and poor survival of patients with early-stage cervical cancer, breast cancer, 
oligodendroglioma, ovarian cancer, endometrial cancer and oropharyngeal 
squamous cell carcinoma (161). Similarly, in a cohort of over 700 colon cancer 
patients overexpression of HIF-1 was shown to be associated with higher colorectal 
cancer-specific mortality, whereas no correlation between HIF-2 expression status 
and patient survival was observed, implying that HIF-1 is the isoform responsible for 
a more aggressive phenotype in this type of malignancy (162). However, association 
between HIF-2 overexpression and increased patient mortality was established for 
non-small-cell lung cancer, head and neck carcinoma, neuroblastoma and 
astrocytoma. Intriguingly, non-small-cell lung and head and neck carcinomas which 
display upregulated expression of HIF-1 have better survival prognosis suggesting 
the possible opposing roles of HIFs in some types of malignancies (161).  
A malignancy example of well understood differential role of HIF subunits is clear 
cell RCC (ccRCC). In about 70% of sporadic ccRCC cases VHL tumour suppressor 
is lost which results in stabilization of HIF subunits (163). However, HIF-1 and HIF-
2 were shown to exert opposing effects on growth of RCC xenografts, with 
overexpression of HIF-1 attenuating and HIF-2 accelerating tumour growth (164). 
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It was further reported, that HIF-2 stimulates c-Myc transcriptional activity and 
therefore cellular proliferation, whereas HIF-1 counteracts this effect in RCC cells 
(143). Consistently, elevated activity of c-Myc and enhanced cell proliferation is 
associated with loss of VHL and stabilization of HIF-2, but not with loss of VHL and 
expression of both HIF-1 and HIF-2 or the presence of intact VHL, in primary 
sporadic RCC tumours (163).  
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4.3. Inflammation 
4.3.1. Inflammation as a mechanism of response to pathogenic insult 
Inflammation is described by four basic characteristics: Lat. calor (heat), Lat. dolor 
(pain), Lat. rubor (redness) and Lat. tumour (swelling) recognized already by Celsus 
in the 1st century. Traits of inflammatory processes are associated with local 
vasodilatation, increased vascular permeability, increased blood flow and fluid 
leakage, as well as accumulation of inflammatory cells at the site of injury (165).  
Great input into understanding of these processes had studies of Elie Metchnikoff 
which in 1882 performed an experiment on a transparent larvae of a starfish pierced 
with a rose thorn. Examination of the larvae on the next day revealed accumulation of 
ameboid cells covering the thorn which, according to him, aimed at engulfing and 
removing the thorn. Metchnikoff was the first to describe phagocytosis as a 
fundamental mechanism by which creatures belonging to the animal kingdom remove 
foreign and potentially dangerous invaders to their organisms (166).  
The immune processes are divided into innate and adaptive responses. Basic 
differences between those two are the time of onset (innate response acts within 
minutes, adaptive requires 4-7 days to develop) and their specificity. Common 
molecular components of pathogens are recognized by innate response, whereas 
specific antigens of a particular invader are detected by adaptive response (165).  
Most of the pathogens activate the innate response first. Tissue macrophages 
directly recognizing molecular markers on pathogens e.g. lipopolysaccharide (LPS), 
which is a component of the outer membrane of Gram-negative bacteria, get 
activated, engulf invaders and produce inflammatory mediators. Those mediators 
include cytokines (modifiers of the behavior of cells carrying a corresponding 
receptor) and chemokines (attractants for cells expressing a cognate receptor). 
Cytokines and chemokines released by activated macrophages initiate the 
inflammation. Also complement, a set of plasma proteins which upon recognition of 
pathogen interact with one another to opsonize (or coat) the invader, can trigger 
inflammatory processes. This occurs through enhancement of phagocytic function of 
cells expressing the receptors against complement coating a pathogen, as well as 
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through release of small pieces of some of its activated components which 
subsequently act as chemoattractants and activators of phagocytes (165).  
The groups of leucocytes involved in innate immunity are granulocytes, 
macrophages, dendritic cells, mast cells and NK cells, whereas adaptive response 
relies on lymphocytes activation. Many infections are successfully eradicated by 
innate immunity, however, when the first line of response fails, adaptive immunity 
mechanisms are triggered (165). 
4.3.2. Cells and their products involved in inflammatory response  
The immune cells (white blood cells, leucocytes) originate from bone marrow and are 
produced from precursor cells common for all blood cellular components – the 
hematopoietic stem cells. Many of the leucocytes maturate also at the site of origin, 
however, some migrate to the thymus or peripheral tissues to accomplish their 
developmental processes. In the bone marrow, initially pluripotent stem cells 
differentiate to lineages which have more specialized and limited potential. Those are 
common lymphoid and common myeloid progenitors (165).  
Common myeloid progenitor lineage specializes to the megakaryocyte/erythrocyte 
progenitor (from which platelets and red blood cells, respectively, develop) and 
granulocyte/macrophage progenitor (which gives rise to granulocytes, macrophages, 
dendritic cells and mast cells) (165).  
Granulocytes (or polymorphonuclear, PMN cells) contain densely stained granules in 
their cytoplasm. Neutrophils are the most common cells among granulocytes. Their 
role relies on the phagocytosis of pathogens and further promotion of inflammatory 
response. Antibody coated parasites are in turn targeted by eosinophils. The role of 
the third kind of granulocytes, basophils, is not yet fully understood, although they 
seem to act similar to the mast cells (described below) (165). 
Macrophages originate from their precursors (monocytes) circulating in blood and 
differentiating upon migration to the local tissues. Their most important role is to 
engulf the pathogen, kill it and release molecular mediators that help attract and 
activate other components of inflammatory response (including neutrophils and T 
lymphocytes, or T-cells). In contrast, dendritic cells (DC) are specialized to 
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phagocytise a pathogen, process it and present its antigens to T-cells (which do not 
recognize antigen unless presented by such antigen presenting cell, APC) (165).  
Mast cells are another group of cells originating from the granulocyte/macrophage 
progenitor cells. Upon their activation, substances increasing vascular permeability, 
including histamine, are released. In addition to their well known role in driving 
allergic reaction, mast cells are also believed to participate in protecting the internal 
body surfaces against infections and play role in response to parasitic worms (165).  
The common lymphoid progenitor differentiates to lymphocytes including B 
lymphocytes (B-cells), T lymhocytes (T-cells) and natural killer (NK) cells. Also some 
portion of dendritic cells develops from the lymphoid lineage (165).  
B-cells originate and maturate in bone marrow, as opposed to T-cells which leave the 
bone marrow to continue the development in thymus. Small naive lymphocytes have 
no functional activity until they encounter the specific antigen as well as get the co-
stimulatory signal from innate immunity response cells. Only after the double 
stimulation is accomplished, the antigen-specific cells start to proliferate and 
differentiate to their functional stage (165).  
Activated B-cells differentiate to plasma cells which secrete antibodies against 
specific pathogen. Released antibodies neutralize viral particles and bacterial toxins, 
opsonize pathogens to enhance their phagocytosis, and activate complement (which 
as mentioned above acts as another coating mechanism, but also creates pores in, 
and therefore destroys some bacteria). The type of immune response associated with 
release of antibodies is known as humoral immunity (165).  
T-cell mediated inflammatory processes are called cellular or cell-mediated immune 
responses of adaptive immunity. Naive T-cells leaving thymus carry mainly CD8 or 
CD4 antigen. Activation of CD8-positive cells results in differentiation to cytotoxic T-
cells (Tc), whereas of CD4-positive in generation of a population of helper T-cells 
(mainly Th1 or Th2).  The role of Tc lymphocytes is killing cells infected with 
intracellular pathogens or transformed cells. Th1 cells have a dual function. On one 
hand, Th1 cells control infections by intracellular pathogens, such as Mycobacterium 
tuberculosis, which may proliferate in a macrophage due to blocking the fusion of a 
phagosome with a lysosome. This infection can be eradicated through activation of 
such an infected macrophage by Th1 cell which recognized bacterial antigen 
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presented on the surface of a phagocyte. On the other hand, activated Th1 cells 
express co-stimulatory signals activating production of antibodies by B-cells. In 
contrast, Th2 cells are responsible exclusively for co-stimulation of B-cells (165). A 
distinct class of T-cells, regulatory (Treg) or suppressor (Ts) cells are negative 
modifiers of action of other lymphocytes providing maintenance of immunologic self-
tolerance (167). 
Other kind of lymphoid lineage-derived cells are the natural killer (NK) cells, which as 
opposed to B and T lymphocytes, do not express antigen-specific receptors and 
belong to the innate immune system. Circulating in the blood, similarly to T 
lymphocytes, those cells are able to recognize and kill intracellular pathogen-infected 
or transformed cells (165).  
Lymphoid organs consist of tissues containing lymphocytes and non-lymphoid cells. 
Those organs are divided into central (primary) lymphoid organs and peripheral 
(secondary) lymphoid organs. Central organs (bone marrow and thymus) are places 
of generation/maturation of lymphocytes, whereas peripheral organs (lymph nodes, 
spleen, mucosal lymphoid tissues) are locations of antigen-specific activation and 
proliferation of lymphocytes, as well as control of their survival (limiting the number of 
circulating lymphocytes). Upon maturation, B- and T-cells enter the bloodstream to 
reach the peripheral lymphoid organs. Immature dendritic cells leave the bloodstream 
to enter tissues where they take up the pathogens. Rapid maturation after 
encountering the pathogen leads to expression of co-stimulatory molecules on the 
surface of dendritic cells, which translocate to the nearest lymph node, subsequently 
activating the T-cells (165). 
4.3.3. Inflammation on the cellular level – NF-B, the master regulator of 
inflammatory responses 
Nuclear factor kappa light chain enhancer of activated B-cells (or nuclear factor-
kappa B, NF-B) was originally discovered over twenty five years ago as an inducer 
of kappa light chains in B lymphocytes (168, 169). It has been well established, that 
NF-B is an ubiquitously expressed dimeric transcription factor induced in response 
to different stimuli.  
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NF-B plays a central role in inflammatory responses by mediating immune cell 
function and promoting inflammation, which is associated with inducing expression of 
different cytokines, chemokines, and their receptors. Furthermore, NF-B inhibits cell 
death in inflammatory conditions by stimulating the transcription of antiapoptotic 
genes (170). However, the response of NF-B is context-dependent and in some 
cases may also elicit cell cycle arrest. In normal human epidermal cells, NF-B and 
overexpression of oncogenic Ras trigger cell cycle arrest, whereas inhibition of NF-
B (by overexpression of IB) prevents oncogenic Ras-mediated induction of 
growth arrest and results in malignant transformation of normal cells (171). 
NF-B dimers continuously shuttle between the cytoplasm and nucleus but the 
balance is strongly shifted towards cytoplasmatic localization in unstimulated 
conditions, and the nucleus upon proinflammatory stimulation. In basal conditions, 
NF-B remains associated with a member of a family of related inhibitory proteins 
(called IBs) among which the prototypical and the most extensively studied is IB. 
IB masks the nuclear localization signal (NLS) of NF-B as well as carries the 
nuclear export signal (NES), which ensure cytoplasmatic localization of NF-B in 
complex with IB. Proinflammatory signalling leads to degradation of IB and 
liberation of NF-B which then translocates to the nucleus and activates its target 
genes (172). 
NF-B acts as a homo- or heterodimer composed of REL homology domain (RHD) 
protein family members including p65/RelA, RelB, c-Rel, p105/p50 (NF-B1) and 
p100/p52 (NF-B2), in mammals. The p65/p50 binding partners represent the most 
abundant dimers being found in almost all cell types (173). However, the prevalence 
of different NF-B dimers in response to proinflammatory stimulation depends on the 
cell type, stimulus and time after exposure (170). The overview of RHD proteins is 
shown in the Figure 2.  
Notably, mice with deletion of p65/RelA display embryonic lethality at the stage E15-
16 due to massive hepatic apoptosis (174). On the other hand, lack of p50 subunit 
expression does not affect the development of mice, but renders them defective in 
the functions of the immune system (175). 
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Figure 2. NF-B subunits. The mammalian RHD protein family is composed of p65/RelA, RelB, c-
Rel, p105/p50 (NF-B1) and p100/p52 (NF-B2) members. RHD – REL homology domain; TAD – 
transactivation domain; LZ – leucine zipper domain; GRR – glycine-rich region; ANK – ankyrin repeat 
domain; DD – death domain (modified from Oeckinghaus A., Ghosh S., 2009). 
The RHD at the N-terminus of RHD family proteins is composed of approximately 
300 amino acids, and mediates binding the inhibitory IB proteins, dimerizartion of 
subunits, nuclear translocation and association to DNA at the consensus B site 5´- 
GGGRNNYYCC-3´ sequence. Only the p65/RelA, RelB and c-Rel carry a 
transactivation domain (TAD), which is located at their C-termini and confers the 
transcription activation ability of NF-B dimers (173).  
RHD proteins p50 and p52 are produced by cleavage of the p105 and p100 
precursor, respectively. Proper processing of p50 and p52 depends on glycine-rich 
region (GRR), which serves as termination signal for their proteosomal degradation. 
Both p105/p50 and p100/p52 are devoid of TAD, therefore those two subunits bound 
to DNA as homo- or heterodimers may act as suppressors of B-dependent 
transcription. C-termini of the p105 and p100 precursors contain ankyrin repeats, 
which are characteristic for the IB family, making them be also members of the 
below described IB group of proteins (173).  
IB family members interact with RHD proteins via ankyrin repeats, and this 
interaction inhibits the nuclear translocation of NF-B dimers. In the majority of 
unstimulated cells inactive NF-B dimers are kept in the cytoplasm by typical IB 
proteins (IB, IB or IB) or precursor RHD proteins p105 and p100. Interestingly, 
atypical members of IB family BCL-3 and IB can be induced upon 
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proinflammatory stimulation and likely ensure the transcription activation properties of 
some NF-B dimers (173). An overview of different IBs is shown in the Figure 3. 
 
Figure 3. IB proteins. IB family represented by typical IBs (IB, IB and IB), precursor RHD 
proteins p105 and p100, as well as atypical members BCL-3 and IB. ANK – ankyrin repeat domain; 
PEST - proline-, glutamic acid-, serine- and threonine-rich region; RHD – REL homology domain; GRR 
– glycine-rich region; DD – death (modified from Oeckinghaus A., Ghosh S., 2009). 
IB and IB bind mainly dimers containing p65/RelA or c-Rel (and IB inhibits 
mainly the most abundant p65/p50 heterodimer). On the other hand, p100 
exclusively captures the RelB subunit. In turn, BCL-3 and IB interact preferentially 
with dimers being combinations of p50 and p52 (173).  
NF-B activation modes are classified as canonical (classical) and noncanonical 
(alternative) pathways. Classical stimulation of NF-B activity is elicited by interleukin 
1 (IL-1), tumour necrosis factor  (TNF-, bacterial products e.g. LPS, or activation 
of antigen receptors. Among noncanonical inducers of NF-B are cluster of 
differentiation 40 ligand (CD40L), B cell activating factor of the TNF family (BAFF) 
and lymphotoxin-(172).  
The canonical mode of NF-B stimulation embraces activation of the IB kinase (IKK 
complex and therefore downstream phosphorylation of the IBs, mainly IB 
followed by its ubiquitination and proteasomal degradation. IKK complex activated in 
canonical pathway consists of one copy of each kinase subunit IKK and IKK and 
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most probably two copies of regulatory IKK (also known as NF-B essential 
modulator, NEMO). Degradation of IB in this pathway is mediated by its IKK-
driven phosphorylation. This event leads to liberation of NF-B (predominantly of the 
classical heterodimer p65/p50), followed by its nuclear translocation and activation of 
target genes. Among them is IkB itself, resynthesis of which is a very important 
negative feedback mechanism controlling the NF-B pathway activity (172).  
In contrast, noncanonical activation of NF-B involves activation of the NF-B-
inducing kinase (NIK) which phosphorylates and activates the IKKkinase. IKK-
mediated downstream phosphorylation of the p100 (NF-B2) subunit in complex with 
RelB, leads to its proteolytic cleavage to p52 and therefore activation of dimers (172).   
Furthermore, atypical activation of NF-B may occur via IKK-independent 
mechanisms. For instance, UV radiation exposure or expression of the Her2/neu 
oncogene leads to phosphorylation and degradation of IB which is mediated by 
casein kinase II (CK2) and independent of IKK (176, 177).  
4.3.4. Toll-like receptor signalling 
The involvement of Toll receptor in the activation of immune responses in a 
Drosophila cell line was shown first in 1995 by Rosetto and colleagues (178). Shortly 
afterwards, a human homologue of Toll gene (hToll) was described (179). Later 
studies revealed the presence of 10 functional members of Toll-like receptors (TLRs) 
in humans and 12 in mice. TLR1-9 are conserved in mice and man, TLR10 is 
dysfunctional in mouse due to retrovirus insertion, whereas TLR11-13 are not present 
in the human genome. Those receptors can be divided into a group expressed on the 
cell surface (TLR1, TLR2, TLR4, TLR5 and TLR11), and a group located in 
intracellular vesicles such as endoplasmic reticulum, endosomes, lysosomes and 
endolysosomes (TLR3, TLR7, TLR8 and TLR9) (180).  
TLRs recognize a whole spectrum of pathogen-associated molecular patterns 
(PAMPs). For instance, LPS of Gram-negative bacteria is a ligand of TLR4 (hToll). 
TLR2, acting as a dimer with TLR1, is responsible for recognition of triacylated 
lipopeptides from Gram-negative bacteria and mycoplasma. The heterodimer 
composed of TLR2 and TLR6 is responsible for signalling diacylated lipopeptides 
from Gram-positive bacteria and mycoplasma. TLR5 detects bacterial flagellin (a 
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component of bacterial flagella). Mouse TLR11, detects profilin-like protein of a 
parasite Toxoplasma gondi and some components of uropathogenic bacteria. TLR3 
recognizes viral double-stranded RNA (dsRNA) and certain small interfering RNAs 
(siRNAs). TLR7 responds to single-stranded RNA (ssRNA) derived from RNA viruses 
such as HIV-1 and influenza A virus, as well as certain siRNAs. Similar function of 
viral ssRNA recognition has its closest relative TLR8. TLR9 is responsible for sensing 
unmetylated CpG motifs in bacterial and viral DNA (180). 
TLRs are composed of an extracellular leucine-rich repeat (LRR) domain (governing 
the recognition of pathogens) and a cytoplasmatic Toll/interleukin-1 receptor (TIR) 
domain (necessary for initiation of intracellular signalling) (181). Activation of the TLR 
signalling results in the upregulation of inflammatory cytokines and chemokines due 
to activation of NF-B transcription factor and MAPKs (which includes downstream 
activation of AP-1). In addition, type I interferon (IFN) response is activated in the 
case of TLR3, -4, -7/8 and -9 receptor stimulation (180).  
After binding the ligand, TLRs interact with the TIR-domain-containing cytosolic 
adapters and this event initiates the signalling cascade. Adapter proteins involved in 
TLR signalling include myeloid differentiation primary response protein 88 (MyD88), 
TIR domain-containing adapter protein (TIRAP), also known as MyD88-adapter-like 
(MAL), TIR domain-containing adapter inducing interferon  (TRIF) and TRIF-related 
adapter molecule (TRAM). Almost all TLRs (except TLR3) utilize MyD88 adapter and 
TLR4 recruits all four of them (180). An overview of the basic principles of TLR 
signalling is shown in Figure 4.  
In MyD88-dependent pathways, the interaction between TLR and this adapter 
recruits interleukin-1 receptor associated kinase 1 and 4 (IRAK1 and 4) (180). First, 
IRAK4 becomes activated upon association with MyD88 adapter. Next, IRAK4 
phosphorylates IRAK1 and this event induces second (autocatalytic) phosphorylation 
and further activation of IRAK1. Hyperphosphorylated IRAK1 interacts with tumour 
necrosis factor receptor-associated factor 6 (TRAF6). Activated TRAF6 mediates 
ubiquitination-dependent downstream signalling leading to NF-B and MAPK 
activation (182). 
MyD88-independent responses upon stimulation of TLR3 or TLR4 signalling proceed 
via TRIF adapter. It was shown by Chang and colleagues, that pellino E3 ubiquitin 
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protein ligase 1 (Peli1) governs the ubiquitination of receptor-interacting protein 
kinase 1 (RIP-1), and is involved in cytokine production in response to stimulation of 
TLR3 and TLR4 receptors (183).  RIP-1 was previously shown to mediate the TRIF-
specific response of NF-B to TLR3 and TLR4 stimulation (184). Furthermore, it was 
also demonstrated that the intracellular death domain (DD)-containing adaptor, 
TNFR1-associated DD protein (TRADD), which can recruit receptor-interacting 
protein kinase 1 (RIP1) upon TNF- stimulation, associates with receptor and 
mediates the TRIF-dependent NFB induction also in TLR4 and TLR3 signalling 
(185). On the other hand, TRIF was also suggested to recruit TRAF6 and therefore 
downstream complex TAB-TAK1 upon TLR3 signalling activation (186).  
Activation of TRIF-adapter-mediated signalling culminates at induction of 
inflammatory cytokines and chemokines, but also secretion of type I interferon, in 
particular interferon-. Transcription of type I interferon is controlled by several 
factors such as NF-B, ATF2/cJun (AP-1) and interferon regulatory factor 3 or 7 
(IRF3 or 7). IRF3 and IRF7 are major controllers of type I IFN response. Similarly to 
NF-B, in unstimulated conditions IRF3 and IRF7 remain inactive in the cytoplasm 
(187). Phosphorylation of IRF3 by noncanonical IKKs, such as TANK-binding kinase 
1 (TBK-1) and IKK(IKK leads to its translocation to the nucleus and target gene 
activation(188, 189). TRIF adapter, recruited to TLR3 and TLR4 signalling, 
associates with TRAF3, which mediates downstream activation of type I interferon 
production recruiting TBK-1 (190).  
Plasmacytoid dendritic cells (pDC) are a subset of DCs which are specialized in 
production of huge amounts of interferon type I in response to viral infection. 
Signalling through TLR7 and TLR9 leading to activation of type I interferons in those 
cells is unusual and depends on MyD88 adapter. Phosphorylation of IRF7 in this 
case, is mediated by IKK and/or IRAK1, which are recruited to MyD88 via IRAK4, 
TRAF6 and TRAF3. In addition, also the signalling to NF-B seems to proceed in a 
specific way in pDCs. Here, activation of IKK complex downstream of TRAF6 does 
not involve TAB-TAK1 (180).  
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Figure 4. Schematic overview of TLR signalling. Almost all TLRs signal via the MyD88 adapter 
except TLR3 which stimulation depends exclusively on the TRIF adapter. The endpoint of activation of 
all TLRs is increased expression of inflammatory cytokines and chemokines, however, TLR3, TLR4, 
TLR7/8 and TLR9 additionally stimulate type I interferons (modified from Kawai T., Akira S., 2007).  
4.3.5. TLR4 pathway 
Stimulation of cells with LPS is possible through a series of interactions between 
different proteins, including LPS binding protein (LBP), CD14, MD-2 and TLR4. CD14 
recognizes LPS bound to LBP (free shuttle protein) and facilitates its transfer to the 
TLR4/MD-2. MD-2 is non-covalently associated with TLR4 and participates in 
recognition of LPS (191). Association of LPS with TLR4/MD-2 results in formation of 
homodimers of TLR4/MD-2-LPS complexes, followed by recruitment of downstream 
TIR-domain containing adapters TIRAP/MAL and MyD88 required for the induction of 
NF-B and MAPKs. Additionally, upon subsequent TLR4 internalization TRAM and 
TRIF adapters are recruited, leading to the activation of NF-B, MAPKs and IRF3 
(180). 
As mentioned above, activation of IRAK kinases takes place upon their recruitment to 
TLR4 via MyD88 adapter. Ultimately IRAK1 kinase binds to TRAF6 (via TRAF6-
binding motifs) thereby stimulating downstream signalling (192). TRAF6 is an E3 
ubiquitin ligase associated with a dimeric E2 ubiquitin conjugating enzyme complex 
composed of UBC13 and UEV1A (UBC-like protein) which together drive Lys 63-
linked regulatory ubiquitination of target proteins, leading to activation of IKK complex 
(193).  
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A complex composed of TGF-activated kinase (TAK-1) and its binding partners 
TAK1-binding protein 1 and 2 or 3 (TAB1-3), becomes activated upon recognition of 
TRAF6-synthetised K63-linked polyubiquitin chains by TAB2/3 through their highly 
conserved zinc finger (ZnF) domain. This leads to phosphorylation-mediated 
autocatalytic activation of TAK-1 kinase, which in turn results in activation of 
IKK(194). 
NEMO/IKK and TRAF6 itself belong to known targets of TRAF6-mediated 
ubiqutination. It has long been thought, that the self-ubiquitination of TRAF6 is crucial 
for its recognition by TAB2/3 and therefore activation of TAK-1. However, it has 
recently been shown, that the autoubiquitination of TRAF6 upon treatment with IL-1 
is dispensable for the activation of the TAB-TAK1 complex, suggesting a role of other 
TRAF6 target(s) in the induction of TAK1 and therefore downstream NF-B and 
MAPK pathways (195). In turn, NEMO/IKK recognizes K63-linked ubiquitin chains, 
as well as becomes K63-ubiquitinated by TRAF6. Intriguingly, ubiquitination of IRAK-
1 by TRAF6, but again not TRAF6 autoubiquitination, was suggested to be 
responsible for interaction of IRAK-1 with NEMO/IKK and therefore its TRAF6-
mediated activation upon TLR/IL-1R stimulation (196). However, unanchored 
ubiquitin chains (not conjugated to any protein) could also activate TAK1 and IKK 
complex (197). 
As mentioned above, NEMO/IKK is also a target of covalent modification with K63-
linked polyubiquitin chains. Impaired cytokine production following TLR agonist 
stimulation (including LPS) in macrophages and DCs derived from knock-in mice 
expressing NEMO/IKK which could not be polyubiquitinated at K392 (K399 in 
human) underscores the importance of this modification in regulating the effect of 
proinflammatory treatment (198). Another study on the role of TRAF6-mediated 
polyubiquitination of both K399 and K285 of NEMO/IKK confirmed, that these 
ubiquitinations are necessary to accomplish optimal TLR4-mediated activation of NF-
B pathway (199).  
As additional level of complication in TLR signalling, Tseng and colleagues 
suggested an important role of TRAF3 in regulation of signalling downstream of both, 
MyD88 and TRIF adapters. TRAF3 and TRAF6 are recruited to both adapters, 
however, cellular inhibitors of apoptosis (cIAP1 and cIAP2), two K48-linked ubiquitin 
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E3 ligases, are recruited only to MyD88. Association between TRAF6 and cIAPs 
leads to their K63-linked ubiquitination and activation. In turn, active cIAPs target 
TRAF3 for proteasomal degradation which allows phosphorylation and activation of 
TAK-1 and downstream MAPKs, but is dispensable for interferon secretion and IKK 
complex activation. On the other hand, TRAF3 associated with TRIF does not 
interact with cIAPs and TRAF3-mediated K63-linked autoubiquitination is necessary 
for induction of type I interferon. Taken together, K48-linked ubiquitination of TRAF3 
upon its recruitment to MyD88 is essential for the activation of MAPKs and production 
of proinflammatory cytokines, but the K63-linked selfubiquitination of TRAF3 
activates the interferon type I production in TRIF-mediated signalling (200). An 
overview of TLR4 signalling pathways is shown in Figure 5.  
To prevent an excessive proinflammatory response, TLR4 signalling can be 
negatively regulated on several levels. RP105 (radioprotective 105), ST2L 
(interleukin 1 receptor, type I, IL-1R1) and SIGIRR (single immunoglobin IL-1R-
related molecule) are surface inhibitors of TLR4 signalling. RP-105, a homologue of 
TLR4, forms complexes with MD-1, a homolog of MD-2. RP-105/MD-1 dimers were 
shown to interfere with the binding of LPS to TLR4/MD-2. In turn, ST2L (a homologue 
of IL-1 receptor) may prevent the activation of TLR4 signalling by sequestering 
MyD88 and TIRAP. Similarly, SIGIRR, another homologue of IL-1R, prevents the 
interaction between TLR4 and MyD88 adapter through its TIR domain (191).  
TLR4 signalling can be inhibited also at downstream levels and this includes 
inhibitory members of the IRAK and TRAF families. For instance, IRAK-M was shown 
to prevent the dissociation of IRAK1 from MyD88, thereby quenching TLR4 
signalling. Similarly, IRAK-2c and MyD88s (splice variants of IRAK-2 and MyD88, 
respectively, which lack functional domains) have been shown to be inhibitory upon 
recruitment to TLR4 signalling. Also some members of TRAF family, such as TRAF1 
and TRAF4, are known as negative regulators of TLR4 signalling. TRIF-dependent 
cleavage of TRAF1 mediates the inhibition of TRIF-induced NF-B and IRF3 
activation in a negative feedback loop. TRAF4 on the other hand, was suggested to 
inhibit NF-B activation when overexpressed, possibly through its interactions with 
TRIF and TRAF6 (191).  
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Figure 5. TLR4-mediated signalling pathways. Activation of the MyD88-dependent pathway results 
in the activation of NF-B and MAPKs. The subsequent (after TLR4 internalization) recruitment of the 
TRIF adapter leads to NF-B, MAPKs and IRF3 activation. 
On another level of negative regulation of TLR4 pathway is action of the 
deubiquitinases (DUBs). A20 (also known as tumor necrosis factor, alpha-induced 
protein 3 - TNFAIP3) is an example of such a modulator, hydrolyzing K63-linked 
polyubiquitin chains on NF-B pathway components.  A20 deubiquitination targets 
are TRAF2, RIP-1 and TRAF6. However, A20 carries also E3 ligase activity, 
therefore it is classified as an “ubiquitin editing” enzyme. The mode of action of this 
deubiquitinase depends on its target. Shortly after proinflammatory stimulation, A20 
is recruited to RIP-1, mediating the hydrolysis of K63-linked polyubiquitin chains on 
RIP-1.  Subsequently, by K48-linked polyubiquitination, A20 mediates RIP-1 
proteasomal degradation. However, although in the case of TRAF6 K63-linked 
ubiquitination is also inhibited in an A20-dependent manner, this negative regulation 
seems to depend on the disruption of the E2:E3 ubiquitin enzyme complex, rather 
than deubiquitination of existing K63-linked polyubiquitin chains. In the next step, the 
E2 enzymes associated with TRAF6 become modified with K48-linked polyubiquitin 
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chains and proteasomally degraded. The Cyld tumour suppressor gene, which is 
frequently mutated in familial cylindromatosis (benign tumours of skin appendages), 
represents an example of another deubiquitinase regulating NF-B signalling. CYLD 
removes K63-linked ubiquitin chains of proteins such as TRAF2, RIP-1, TRAF6 and 
NEMO/IKK. Despite sharing some target genes, A20 and CYLD are not redundant. 
CYLD is responsible for quenching undesired NF-B activity in unstimulated 
conditions, whereas A20 inhibits the NF-B signalling elicited upon proinflammatory 
stimulation (in a negative feedback loop since A20 is a NF-B target gene). CYLD-
mediated control of NF-B activation is transiently abrogated by interacting with 
activated NEMO/IKK and phosphorylating of CYLD by IKK, thereby the stimulus-
elicited signalling to NF-B becomes possible (201).   
4.3.6. The role of NF-B in the intestinal epithelium 
The lumen of the guts is inhabited by trillions of commensal bacteria, whereas the 
intestinal mucosa contains large number of immune cells. Therefore, the interaction 
between microbiota and immune system of this site must be precisely controlled to 
avoid undesired intestinal inflammation (202). The epithelium of the gastrointestinal 
track in an adult person covers approximately 300 m2 and composes an efficient 
barrier from the body exterior environment (203). Intestinal epithelium response 
triggered by activation of pattern recognition receptors (PRR), such as toll-like 
receptors (TLRs) and nod-like receptors (NLRs), by intestinal commensal microbiota 
include NF-B-mediated upregulation of regulators of intestinal immune cells 
activation such as cytokines and chemokines, as well as antimicrobial peptides (202). 
Therefore, except from physically separating mucosal immune system from the 
luminal content of the guts, intestinal epithelium (mainly the Paneth cells of the small 
intestine) secreting antimicrobial peptides such as defensins limit the amount of 
bacterial flora and shape the microbiome composition (202, 204). However, NF-B 
plays also an important antiapoptotic function in the physiology of gut epithelium. 
Mice with intestinal epithelium-targeted deletion of NEMO/IKK or both kinases IKK 
and IKK were shown to spontaneously develop sever chronic inflammation in the 
guts. Deficiency in NF-B signalling was associated with increased intestinal 
epithelium apoptosis, decreased synthesis of defensins and excessive flux of 
commensal bacteria into the mucosa, triggering intestinal inflammation. Furthermore, 
global knock-out of TNF- receptor TNFR1 abrogated inflammation induced by the 
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lack of  NEMO/IKKexpression in intestinal epithelium, an effect at least partially 
dependent on TNF- induced epithelial apoptosis and thereby impaired integrity of 
intestinal epithelium layer in the absence of NEMO/IKK (205). Although persistent 
activation of NF-B signalling in intestinal epithelial cells such as in mice expressing 
constitutively active IKK in this cell type was found to be associated with immune 
cells infiltration as well as increased production of cytokines and chemokines, 
animals developed only mild inflammation in the guts (206). However, strong 
sensitization to inflammation elicited by intestinal damage-inducing agent dextran 
sulfate sodium salt (DSS) could be observed (206, 207). Collectively, those studies 
provided evidences that the proper function of intestinal epithelium is mediated by 
tight regulation of NF-B activation level.     
4.3.7. Inflammation, NF-B and cancer  
Inflammation may precede the development of malignancy or originate from genetic 
alterations leading to both inflammation and neoplasia (24). The link between chronic 
inflammatory processes and the development of cancer is well established for 
example in the case of inflammatory bowel disease (IBD) and colitis-associated 
cancer (CAC) (208, 209). However, activation of inflammatory processes during the 
course of tumourigenesis can be established due to dysregulated expression of NF-
B pathway members as well as mutations in oncogene/tumour suppressor genes 
(210-213). 
Increased activity of NF-B in tumours is associated with poorer prognosis of cancer 
patients including colorectal, pancreatic, nasopharyngeal, ovarian, esophageal, lung 
and cervical malignancies (214-220). In addition to protumourigenic effects of 
inflammatory pathways activation in cancer cells themselves, NF-B (in concert with 
signal transducer and activator of transcription 3, STAT3 and HIF-1) drives innate 
immune cell infiltration into the tumour microenvironment. The infiltrating cells, 
together with activated cancer and stromal cells, are responsible for further NF-B, 
STAT3 and HIF-1-mediated production of inflammatory mediators such as 
chemokines, cytokines and prostaglandins. This cumulative action of different cells in 
cancer microenvironment promotes infiltration of more leucocytes, as well as sustains 
the activation of leucocytes, stromal and cancer cells, facilitates tumour cell survival 
and proliferation, and stimulates migration, invasion, angiogenesis, 
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lymphangiogenesis and metastasis, as well as inhibits adaptive anticancer immunity 
and contributes to cancer therapy resistance (24). 
A well known example picturing the in vivo roles of cancer cell- and myeloid-derived 
NF-B in colorectal carcinogenesis is a study by Greten and colleagues (221). In this 
report, a mouse model with a targeted deletion of IKK (unable to activate NF-B) in 
colonic epithelial cells reveled decreased colon cancer incidence upon combined 
treatment with procarcinogen azoxymethane (AOM) and an inducer of colonic 
inflammation DSS. This effect was associated with increased epithelial apoptosis 
during early steps of tumourigenesis. Lack of IKK however, did not affect the 
tumour dimensions (221). In line, expression of constitutively active IKK 
(permanently stimulated NF-B) in enterocytes spontaneously induced tumours in 
aged mice, as well as strongly promoted AOM/DSS- and Apc mutation-induced 
carcinogenesis (207). However, targeted deletion of IKK in the myeloid lineage did 
not affect tumour incidence, but resulted in decreased tumour size, suggesting 
myeloid cell-derived NF-B to be an important regulator of cancer growth (221).  
The key NF-B-target genes abundantly secreted in cancer microenvironment are 
TNF-and IL-1 (inducers of NF-B), as well as IL-6 (activator of STAT3). The effects 
of TNF-, IL-1 and IL-6 in cancer due to activation of mentioned transcription factors 
are associated with promoting premalignant and malignant cell survival and 
proliferation, as well as their ability to maintain the cancer-related inflammation (222).  
Expression of NF-B-targeted adhesion molecules such as E-selectin, intracellular 
cell adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) 
regulates adhesion and migration of the leucocytes, processes involved in 
physiological inflammation as well as cancer-elicited inflammation (223).  
NF-B target genes can be directly involved in modulation of cancer cell survival. 
Inhibitors of apoptosis, such as BCL-XL, BCL-2, cIAP1, cIAP2, MCL-1, c-FLIP and 
survivin, are regulated by NF-B. However, distinct cell types depend on the 
expression of those regulators to different extent e.g. BCL-XL appears to be a major 
antiapoptotic factor in enterocytes, whereas c-FLIP seems to be its counterpart in 
hepatocytes (224).  
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NF-B participates in the regulation of motility, invasiveness and metastasis. Twist is 
a known repressor of E-cadherin mediating EMT in cancer metastasis (225). Twist 
was shown to be transcriptionally activated by NF-B in normal breast epithelia and 
breast carcinoma cell lines treated with TNF- Furthermore, overexpression of 
p65/RelA was sufficient to induce EMT and the knock-down of Twist attenuated 
p65/RelA overexpression-mediated EMT, migration and invasiveness, underscoring 
the role of NF-B in induction of aggressiveness of breast cancer cells (226). 
Moreover, EMT induction by NF-B with potential involvement of other transcriptional 
repressors ZEB-1 and ZEB-2, factors of known role in downregulation of E-cadherin, 
was shown to occur in non-transformed mammary epithelial cells (227).  
Furthermore, iNOS/NO, COX-2/prostaglandin E2, as well as MMP2 and MMP9 are 
other well established NF-B-regulated players in cancer (228-231). Their roles were 
described in detail in the chapter 4.2.3.  
4.3.7.1. Immune cells in carcinogenesis 
Solid tumours contain immune cells such as macrophages, neutrophils, mast cells, 
MDSC, dendritic cells, natural killer (NK) cells, T- and B-cells, coexisting with cancer 
cells and their stroma (fibroblasts, endothelial cells, pericytes and mesenchymal 
cells) (224).  
The mediators of macrophage infiltration from blood monocytes to the tumour are 
tumour-derived chemokines including chemokine (C-C motif) ligand 2 (CCL2) also 
known as monocyte chemotactic protein-1 (MCP-1), CCL5 (RENTES), CCL7 (MCP-
3), CCL8 (MCP-2), and chemokine (C-X-C motif) ligand 1 (CXCL1), also known as 
growth-regulated alpha protein (Gro-. Furthermore, infiltration of macrophages is 
induced by growth factors such as VEGF, PDGF, TGF and macrophage colony-
stimulating factor (M-CSF) (232). Tumour homed blood monocytes may polarize to 
dysplay M1-like (classical activation, antitumourigenic) or M2-like (alternative 
activation, protumourigenic) phenotype, dependent on cytokines present in the 
tumour microenvironment (233). At the site of inflammation, IFN-(produced mainly 
by activated Th1, Tc and NK cells) andLPS elicit activation of M1 phenotype 
macrophages displaying strong proinflammatory properties. M2 macrophage 
activation results from stimulation with IL-4 or IL-13 (M2a), immune complexes 
combined with LPS or IL-1M2b and IL-10, TGF- or glucocorticoids (M2c) (234).  
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High ratio of M1/M2-like macrophages present in some human cancers including 
ovarian and gastric tumours, or high content of M1-like macrophages for instance in 
nonsmall cell lung cancer (NSCLC) and gastric cancer, were reported to positively 
correlate with a better patient outcome (25-28). However, tumour-associated 
macrophages (TAMs) usually display M2-like protumourigenic, rather than M1-like 
phenotype of strong antitumor potential. High content of M2-like polarized 
macrophages in human malignancies such as uveal melanoma and pancreatic 
cancer have been found to be associated with worse patient prognosis (29, 30).  
M1 polarized macrophages are well established activators and effectors of the Th1-
mediated response, which helps to eliminate intracellular pathogens as well as 
cancer cells. M2 macrophages are characterized by the ability to inhibit Th1 cells, 
poor antigen presentation capacity, scavenging of debris, promoting tissue 
remodeling and angiogenesis, next to their role in promoting Th2 response (and 
therefore elimination of parasites). M1 macrophages efficiently produce ROS as well 
as potent proinflammatory cytokines such as IL-1, TNF- and IL-6, whereas M2 
macrophages produce rather small amounts of ROS and variable levels of 
inflammatory cytokines. Importantly, M1-activated macrophages display high 
expression levels of IL-12 and IL-23, and only low production of IL-10. Conversely, 
the M2-polarized class secretes little IL-12 and IL-23, and higher amounts of IL-10, 
making polarized macrophages important modulators of the antitumour immune 
responses (232).  
IL-12 induces NK cells proliferation and their IFN- production, as well as elicits Th 
cells differentiation towards Th1 (further very efficient producers of IFN- which 
results in the enhancement of cytotoxic T cells activity. In addition, IFN- enhances 
the tumour antigen presentation in the context of MHC I, contributing to tumoricidal 
cytotoxic T cells action by potentiating target cell recognition, among other functions. 
However, IL-23 inhibits infiltration and function of cytotoxic T-cells, although the 
mechanism of this effect is not fully understood. Therefore, the local balance between 
the availability of IL-12/IFN- and IL-23 in the tumour microenvironment seems to 
determine the efficiency of immunosurvaillance by cytotoxic T-cells (235).  
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IL-23 secreted by macrophages and cancer cells propagates IL-17-secreting subset 
of T-cells. Subsequently, secretion of IL-17 and signalling downstream of IL-17 
receptor results in expression of proinflammatory effectors including IL-1, IL-6, TNF-
, IL-8 and prostaglandin E2, which further participate in the maintenance of cancer-
related inflammation (235). Of note, it has recently been shown that IL-17 acting via 
Act1 ubiquitinase activates TRAF6, which in turn induces NF-B pathway (236).  
IL-10, which was discovered first as a Th2-produced factor inhibiting Th1 cytokines 
secretion, is highly expressed by M2-polarized TAMs, and functions as strong 
autocrine immunosuppressant attenuating NF-B activation and IL-12 expression, 
therefore inhibiting macrophage antitumour activity (237, 238).  
TAMs further contribute to the inhibition of anticancer immunity by production of 
CCL17 and CCL22 chemokines, which are responsible for recruitment of suppressor 
T and Th2 cells (239). Furthermore, TGF- secreted by TAMs plays a role in this 
aspect of carcinogenesis by inhibiting IFN- production in Tc and Th1 cells, as well as 
by stimulating development of suppressor T cells (240). 
Further roles of TAMs in cancer embrace promotion of malignant cell survival and 
proliferation, extracellular matrix (ECM) remodeling, angiogenesis, invasion and 
metastasis, by secreting huge amounts of effectors such as MMPs, plasmin, uPA, 
uPAR, TGF-, VEGF, epidermal growth factor (EGF) and IL-8 (232).  
Since the functions of macrophages and lymphocytes are inseparably connected to 
one another, some roles of lymphocytes were described above. However, the 
importance of distinct T cell subpopulations in cancer underscores the association 
between their detection in tumour microenvironment and the patient outcome. For 
instance, in colorectal cancer infiltration of Tc and Th1 cells was associated with 
better patient prognosis (241). On the other hand, the presence of Th17 cells was 
correlated with poor disease-free survival in another study in the same type of cancer 
(242). Similarly, increased number of suppressor T cells is associated with poor 
prognosis in several cancers including ovarian, breast, non-small cell lung, 
hepatocellular, renal, pancreatic, gastric and cervical cancers (243). The latter may 
exert their tumour-promoting effect by inhibiting the activation of Th and Tc cells 
(240).  
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Tumour-associated neutrophils (TANs) accumulate in the cancer microenvironment 
owing to cancer-derived expression of chemokines such as IL-8, CXCL1 CXCL2 and 
CXCL3. By analogy to macrophage polarization phenotypes, there are two distinct 
types of neutrophils, N1 and N2. TANs of N2 protumourigenic phenotype result from 
stimulation with TGF-. Accumulation of TANs in the tumour is associated with 
increased ROS production and DNA damage, as well as pronounced secretion of 
VEGF and MMP9 (232). Importantly, increase infiltration of neutrophils was found to 
be associated with adverse patient prognosis for example in colorectal cancer and 
esophageal squamous cell carcinoma (244, 245) .  
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4.4. Colorectal cancer, a model to study the interplay between hypoxic 
and inflammatory pathways 
Colorectal cancer (CRC) is one of the most common human malignancies, which in 
2012 accounted for 1.36 million diagnosed new cases and 694 000 cancer-related 
deaths worldwide. It is the second most common malignancy in women and the third 
in men. The risk of developing colorectal cancer by age of 75 amounts to 1.95%, 
which makes it the highest after malignancies of breast, prostate and lung (1).  
The luminal side of the small intestine surface forms circular folds (also known as 
folds of Kerckring) each of which displays further protrusions called villi. Villi are 
finger-like structures covered mainly with adsorptive enterocytes and mucus-
producing goblet cells. Other terminally differentiated cell-types of intestinal 
epithelium are peptide hormone-secreting endocrine cells and Paneth cells (mainly in 
small intestine, secreting antimicrobial peptides). Microvilli are cell membrane 
extensions on epithelial cells which form the “brush border” membrane of the 
intestine.  Intestinal mucosa (or mucous membrane) is formed by a monolayer of 
epithelial cells placed on lamina propria (underlying loose connective tissue), as well 
as a layer of smooth muscles called muscularis mucosae. The connective tissue of 
the mucosa contains capillary vessels, neurons and immune cells, such as mast 
cells. Submucosal layer, loose connective tissue located below mucosa, contains 
larger blood vessels and may also carry glands. Submucosa is surrounded by two 
additional smooth muscle layers, forming muscularis externa (circular and 
longitudinal muscle layers), and a serous membrane (79). Invaginations of the layer 
of epithelial cells into the underlying lamina propria form intestinal crypts (also known 
as crypts of Lieberkühn). The crypts contain multipotent stem cells (SCs) located at 
their bottom, which can give rise to any of the intestinal epithelial cell (246). A 
schematic organization of the intestinal wall is shown in Figure 6. The SCs of colonic 
crypts divide mostly asymmetrically into one daughter cell being identical to the 
original cell, and one becoming a progenitor differentiating into other cell types. 
During divisions progenitors migrate to the top of a crypt reproducing all the 
terminally differentiated intestinal cell types (247). The crypt SCs are the cells from 
which intestinal cancer originates (248). 
CRCs are generally divided into sporadic, inherited and colitis-associated cancers. 
Sporadic cases account for about two thirds of the total number of CRC. In up to one 
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third of cancer patients moderate inheritance (familial clustering) is observed. Well 
known hereditary conditions, including familial adenomatous polyposis (FAP) 
syndrome and Lynch syndrome (hereditary non-polyposis colorectal cancer, 
HNPCC), are associated with about 3 - 5% of colorectal cancers (249). Finally, 
Colitis-associated cancers (CACs) represent about 1 - 2% of all cases (250). 
 
 
Figure 6. Organization of the intestinal wall. The intestinal wall is organized out of four main layers: 
mucosa, submucosa, muscularis externa and serosa. Invaginatons of epithelial cell layer towards the 
underlying lamina propria form intestinal crypts. Lamina propria contains capillary vessels, neurons 
and immune cells (not shown). 
However, although CACs are in minority, the cumulative risk of developing CRC in 
patients with IBD is up to 18% in ulcerative colitis (UC) and up to 8.3% in Crohn`s 
disease (CD) 30 years upon IBD diagnosis (208, 209). Furthermore, be it the case of 
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colitis-associated cancer or not, inflammatory infiltrate and expression of 
proinflammatory cytokines are often present in CRCs (251).  
The colon of humans is inhabited by about 1014 commensal microorganisms, 
representing a huge range of species diversity (252). The importance of microflora in 
CRC underscores the decreased number and size of chemically-induced tumours in 
germ-free rats compared to animals harboring regular gut micoroflora (253). The 
main constituents of colon microflora are Gram-negative bacteria, and their outer 
membrane component LPS is recognized by TLR4 (254). Interestingly, TLR4 knock-
out mice were protected from tumours in a model of AOM/DSS-induced colon 
carciongenesis, indicating a role of TLR4 signalling in the development CAC (255).      
Majority of the TLRs in healthy guts are expressed in antigen presenting cells, 
whereas intestinal epithelial cells display much lower levels of TLRs (254). However, 
TLR4 receptor as well as its adapter MyD88, were shown to be overexpressed in 
tumour cells compared to surrounding normal and adenomatous epithelium in human 
sporadic colon cancers, and expression of TLR4 and MyD88 was associated with 
poor patient prognosis (256). Similarly, over 90% of analysed human CAC expressed 
high levels of epithelial TLR4 (257). Consistently, overexpression of TLR4 in mouse 
colonic epithelium results in formation of more numerous tumours in response to 
AOM/DSS-induced carcinogenesis compared to WT mice (257).  
The presence of hypoxia is characteristic for CRCs and the overexpression of HIF-1 
in CRC implies worse patient prognosis (162, 258). Similarly, almost all CAC and 
most of other CRCs display activation of NF-B and an increase of NF-B activity in 
colorectal patients is associated with poorer clinical outcome (214, 251, 259). 
Therefore, colorectal cancer deserves special attention with regard to the possible 
crosstalk between hypoxic and inflammatory pathways. 
  
Introduction 
 
54 
 
4.5. Connections between hypoxia/HIF and inflammation/NF-B 
Some connections between hypoxia/HIF and inflammation/NF-B were already 
discussed before. However, the established links between those two responses 
make more comprehensive picture. It is widely understood that hypoxia may develop 
at the site of inflammation, for instance owing to increased distance to the vessels 
(due to edema) or elevated oxygen consumption (linked to ROS production by PMN 
cells in oxidative burst) (203). Inflammatory bowel disease model in mice revealed a 
prominent increase in the extent of hypoxia compared to healthy animal colonic 
mucosa, proving inseparable presence of hypoxia during the course of chronic 
inflammatory condition in the guts (260). On the other hand, hypoxia facilitates cell 
survival and function at the site of inflammation. HIF-1-mediated induction of 
glycolysis is indispensable for the maintenance of the cellular ATP levels in myeloid 
cells, and therefore their inflammatory function (261). In addition, survival of 
neutrophils in hypoxia was shown to be mediated by HIF-1-dependent NF-B 
activation (262).  
Furthermore, a direct transcriptional regulation of HIF-1 mRNA by NF-B pathway 
has been described in different experimental models, including rat macrophage-like 
(NR8383) cells, human embryonic kidney (HEK) 293, pulmonary artery smooth 
muscle cells (PASMCs), mouse macrophage-like (RAW247.6) cells, human 
monocytic cell line (THP-1) (also following differentiation), primary human 
macrophages, bone marrow-derived macrophages (BMDMs) as well as in vivo in the 
livers and brains of mice (263-268). Some groups observed, however, an increase in 
HIF-1 protein levels following proinflammatory stimulation with no changes of its 
mRNA abundance, uncovering the existence of other mechanisms of NF-B-
mediated HIF-1 expression regulation (269-271). For instance, stabilization of 
ubiquitinated HIF-1 protein associated with VHL after TNF- treatment in HEK293 
and porcine kidney cells LLC-PK1 (269).  In other work, stimulation with IL-1 was 
found to upregulate HIF-1 protein levels in human lung carcinoma A549 cells with 
the involvement COX-2/prostaglandin E2 synthesis pathway (270). Direct 
transcriptional NF-B-mediated regulation of HIF-1 mRNA was also reported (272). 
Furthermore, NEMO/IKK was shown to interact with HIF-2but not HIF-1), and 
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therefore enhance its transcriptional activity by recruiting p300/CBP transcriptional 
co-activators (273). 
According to some reports hypoxic treatment activates NF-B pathway. The 
suggested mechanisms embrace PHD1 inhibition-dependent de-repression of IKK 
kinase in HeLa cells exposed to hypoxia (274). Curiously, exposure to hypoxia 
induced NF-B in osteosarcoma cell line U2OS, breast carcinoma MDA-MB-231 and 
nontransformed breast epithelial cell line MCF10A (275). This effect was found to be 
associated with calcium/calmodulin-dependent kinase 2 (CaMK2)-mediated IKK 
complex activation, which in contrast to other IB phosphorylation-inducing 
pathways, did not lead to the degradation of NF-B  inhibitor, but its sumoylation 
(275). In other study, HPV-encoded E6 protein was reported to mediate inactivation 
of deubiquitinase CYLD and therefore prolonged hypoxic activation of NF-B in cell 
lines infected with high risk HPV (276). Moreover, study in neutrophils showed 
transcriptional targeting of p65/RelA by HIF-1 in hypoxia (262).  
The effects of proinflammatory stimulation under hypoxia or following PHD enzyme 
inhibitor treatment differ compared to control conditions. TNF--elicited NF-B 
activation, in HeLa and HEK293 cells, was shown to be increased in hypoxia 
compared to normoxia (274, 277). However, treatment of Raw264.7 macrophages 
with the PHD inhibitor dimethyloxalylglycine (DMOG), or shRNA targeting PHD1 or 
PHD2, suppressed the cytokine expression in response to LPS (278). Interestingly, 
pharmacological hypoxia in rheumatoid arthritis synovial fibroblasts enhanced 
proinflammatory cytokine production following the treatment with agonists of TLR2, 
TLR3 and TLR9, but attenuated the cytokine response to TLR4 stimulation (279). 
Finally, Scholz and colleagues showed, that the magnitude of NF-B activation with 
IL-1 is decreased after DMOG pretreatment in HeLa cells and in vivo in reporter 
mice, in a manner dependent on combined PHD1 and FIH inhibition (277). 
There are plenty of data indicating a role of PHDs/HIFs in the modulation of the 
course of inflammatory bowel disease. Treatment with DMOG resulted in 
amelioration of DSS-elicited colitis in a manner at least partially dependent on gain of 
intestinal epithelial antiapoptotic phenotype (280). Consistently, PHD1-/- (but not 
PHD2+/- or PHD3-/-) mice were less susceptible to experimentally induced colitis, 
associated with increased density of colonic epithelial cells due to decreased 
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apoptosis, and therefore enhanced epithelial barrier function. In line, levels of PHD1 
were increased in mice with experimentally induced colitis, whereas in patients 
suffering from IBD, PHD1 expression positively correlated with the severity of the 
disease (281).  
As shown in vivo in a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-
induced colitis, extensive mucosal hypoxia and concomitant HIF-1 activation 
accompanied colitis. Intestinal epithelium-specific depletion of HIF-1 positively 
correlated with severity of clinical symptoms (such as weight loss, colon shortening, 
mortality), whereas constitutive activation of HIF-1 was protective in the same model 
of colitis. The effect of hypoxia/HIF-1 was reflected by the increased expression 
levels of known epithelial barrier-protective HIF targets, including multidrug 
resistance 1 (MDR1), intestinal trefoil factor (ITF) and ecto-5'-nucleotidase (CD73) 
(260).  
In contrast, the studies by Xue and colleagues showed HIF-2 role in exacerbating 
experimentally-induced colitis. In this work, HIF-2 levels were shown to be 
increased in mice with experimentally induced colitis, as well as in patients suffering 
from ulcerative colitis and Crohn`s disease. Intestinal epithelial depletion of HIF-2 
reduced the robustness of inflammation in DSS or Citrobacter rodentium-induced 
mouse models of colitis. Consistently, overexpression of HIF-2 (but not HIF-1) led 
to the development of spontaneous colitis, as well as increased susceptibility to DSS 
or C. rodentium-induced colitis. HIF-2 mediated the activation of an inflammatory 
response through the induction of TNF-, and TNF- inhibition abrogated the effect 
of HIF-2 overexpression on colitis (282). Recent report on the association between 
aircraft travel or journeys to altitudes of more than 2000 meters above sea-level with 
increased risk of flare-up events in patients with IBD, further suggested that PHD/HIF 
system might play a context-dependent role in regulation of the inflammation in 
chronic inflammatory disease in the intestines (283).  
Interestingly, xenografts of human colon cancer DLD-1 cells with stable HIF-1 
knock-down displayed decreased volume and weight, as well as increased infiltration 
of inflammatory cells (mainly neutrophils), but the tumour angiogenesis was 
sustained. Mechanistically, in the absence of HIF-1 hypoxic ROS production was 
shown to induce NF-B-driven production of proangiogenic IL-8, which sustained the 
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angiogenesis (51), suggesting the existence of certain level of interconnection of HIF-
1 and NF-B pathways is colon cancer cells. However, the resultant of the 
concomitant hypoxia/HIF-1activation and inflammation/NF-B induction in colon 
cancer remains currently unknown and needs comprehensive studies, given the fact 
that both HIF-1 and NF-B are prominent players in this malignancy.  
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5. Aims of the thesis   
 
 Study the relevance of hypoxic and inflammatory environmental conditions in 
colon cancer using mouse colon adenocarcinoma MC-38 cells as a model. 
 
 Analyse the putative response of the HIF pathway to inflammatory stimulation 
as well as the NF-B pathway to hypoxia in MC-38 cells. 
 
 Test the requirement of the HIF pathway for NF-B, and the NF-B pathway 
for HIF 
 
 Investigate the potential interplay between hypoxic and inflammatory pathways 
upon simultaneous stimulation of HIF and NF-B in MC-38 cells.   
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ABSTRACT 
Two main features common to all solid tumours are tissue hypoxia and inflammation, 
both of which cause tumour progression, metastasis, therapy resistance and 
increased mortality. In addition, chronic inflammation is associated with increased 
cancer risk, as demonstrated for inflammatory bowel disease patients developing 
colon cancer. Here, we show that MC-38 mouse colon cancer cells contain functional 
hypoxic (HIF-1 stabilization by low oxygen) and inflammatory (p65/RelA nuclear 
translocation by LPS) signalling pathways. In contrast to cells of the myeloid lineage, 
neither was HIF-1 regulated by an inflammatory stimulus nor was NF-B induced by 
hypoxia. To analyse the interplay between these two pathways, HIF-1 and p65/RelA 
were stably knocked-down by viral transduction with shRNA expression vectors, and 
MC-38 cells were cultured as small 3D tumour spheroids which increased the 
inflammatory responses without affecting HIF-1 levels. RNA deep sequencing 
revealed that a surprisingly large fraction of HIF target genes required p65/RelA for 
hypoxic regulation and a number of p65/RelA target genes required HIF-1 for 
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inflammatory regulation. Of note, hypoxia attenuated the NF-B-mediated 
inflammatory response to LPS. Mechanistically, hypoxia was found to inhibit nuclear 
translocation of p65/RelA which was associated with enhanced IB levels, 
independently of HIF-1. In summary, these data demonstrate a thight interaction of 
hypoxic and inflammatory signalling pathways which is clearly different between 
cancer and myeloid cells. 
 
Key words: hypoxia-inducible factor, inflammatory bowel disease, lipopolysaccharide, 
NF-B, tissue oxygenation, tumour hypoxia. 
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INTRODUCTION 
The growth of solid tumours is associated with the presence of tissue hypoxia 
(insufficient oxygen supply) and accompanied by leukocyte infiltration (inflammation), 
both of which further affect the metabolism of cancer cells, thereby regulating 
proliferation, metastasis and therapy efficacy (284). Hypoxia-inducible factor (HIF) is 
the master regulator of the hypoxic response in cancer cells (81). HIFs are 
heterodimeric transcription factors consisting of one out of three different oxygen-
sensitive HIF subunits and a common constitutive HIF subunit. A family of prolyl-4-
hydroxylase domain (PHD) enzymes covalently modifies two proline residues within 
the oxygen-dependent degradation (ODD) domain of HIF subunits. The PHD family 
comprises three members called PHD1, PHD2 and PHD3. Upon hydroxylation under 
normoxic conditions, HIF is bound by the von Hippel-Lindau (VHL) tumour 
suppressor protein and targeted for proteasomal destruction. The resulting high 
turnover rate of HIF subunits allows for a very rapid stabilization under hypoxic 
conditions, affecting the transcriptional activity of several hundred target genes (285). 
Tumour hypoxia and high HIF levels are associated with poor prognosis of virtually 
all cancer types (286). 
 
The association between inflammatory bowel disease and colon cancer is one 
example demonstrating that chronic inflammation pre-disposes to cancer (287). 
Conversely, antiinflammatory drugs decrease the incidence of cancer (24). Invading 
inflammatory cells represent a remarkable proportion of the total tumour mass and 
they are required for tumour angiogenesis and metastasis (52). The nuclear factor 
(NF)-B is the central transcription factor activated in inflammation. Canonical NF-B 
activation is controlled by inhibitor of NF-B (IB) kinases (IKK), mainly IKK-, 
needed for phosphorylation-induced degradation of IB in response to infection and 
inflammation (288). Like HIF-1, NF-B can be activated in tumours by extrinsic 
factors (e.g. autoimmune disease) or intrinsic factors (e.g. oncogenes) (24). In cancer 
cells, NF-B regulates the expression of genes involved in several processes that 
play key roles in tumour progression such as proliferation, migration and apoptosis 
(289). 
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Whether or not NF-B can also be induced by hypoxia is currently unclear. While 
some groups reported increased NF-B activation under hypoxic conditions, others 
could not detect an increased NF-B DNA-binding activity in hypoxic nuclear 
extracts, despite strongly induced HIF levels (290-294). This might be explained by 
the severity and duration of the hypoxic stimulus which may be specific for induction 
of distinct transcription factors. However, IKK- has been reported to be a specific 
PHD1 oxygen sensor target (291), and the ankyrin repeats of p105 NF-B precursor 
and IB have been shown to be hydroxylated by factor inhibiting HIF (FIH), albeit 
without any functional consequences (295). Interestingly, in neutrophils the transcript 
abundance of p65/RelA was shown to be induced by hypoxia in a HIF-1-dependent 
manner. Consistently, hypoxia increased the levels of p65/RelA protein and NF-B 
transcriptional activity (262).  
 
The gene encoding HIF-1 has been suggested to be a NF-B target. So far, TNF, 
oxidative stress and bacterial infections have been shown to activate HIF1a gene 
transcription via NF-B (296-300). A role for NF-B in enhancing HIF-dependent 
tumour progression via inflammatory NF-B activation has not been investigated yet. 
To better understand the mutual regulation of hypoxia and inflammation signalling 
pathways in cancer, we studied their interaction in the mouse colon carcinoma cell 
line MC-38. 
 
RESULTS 
The hypoxic response of MC-38 colon cancer cells is mediated by HIF-1 
Mouse MC-38 colon adenocarcinoma cells were exposed to normoxia (21% oxygen) 
or hypoxia (0.2% oxygen) for 8 to 72 hours using conventional two-dimensional (2D) 
dish culture, and mRNA levels of HIF-1 and HIF-2 were determined by RT-qPCR. 
Whereas hypoxia did not upregulate HIF-1 mRNA levels (Figure 1A), it robustly 
induced HIF-1 protein accumulation (Figure 1B). In contrast, only marginal HIF-2 
mRNA levels (Figure 1A) and no HIF-2 protein (data not shown) could be detected, 
suggesting that HIF-1 rather than HIF-2 mediates the hypoxic response in MC-38 
cells. No difference in viability and only slightly decreased proliferation rates were 
observed under hypoxic conditions (data not shown). Transcript levels of the three 
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canonical HIF target genes Glut1, Ca9 and Phd3 were found to be maximally 
upregulated by 12, 146 and 23-fold, respectively, with different kinetics (Figure 1C). 
 
A proinflammatory stimulus activates the NF-B pathway in MC-38 colon 
cancer cells  
While the activation of the inflammatory NF-B pathway by lipopolysaccharide (LPS) 
is well established mainly in the myeloid lineage, it is less clear whether all 
components of this pathway are also active in carcinoma cells. Therefore, we 
stimulated 2D cultured MC-38 colon cancer cells with LPS and analysed p65/RelA 
subcellular localization by immunofluorescence (Figure 2A) and by immunoblotting of 
nuclear extracts (Figure 2B). LPS induced nuclear translocation of p65/RelA, 
demonstrating a functional LPS signalling pathway resulting in NF-B activation. This 
conclusion was confirmed by a robust mRNA induction of the canonical NF-B target 
genes Tnfa and Cox2 which were significantly induced by 13- and 4-fold, 
respectively, with different kinetics (Figure 2C). Similarly, IL-6 mRNA was found to be 
12-fold upregulated by LPS, though not reaching statistical significance (Figure 2C).  
 
NF-B is not activated by hypoxia in MC-38 colon cancer cells 
It has been suggested that hypoxia directly activates the NF-B pathway by blocking 
PHD-mediated hydroxylation of IKK-, at least in HeLa cervical carcinoma cells 
(291). However, in contrast to LPS treatment, exposure of MC-38 colon carcinoma 
cells to hypoxia for 0.5 to 4 hours did not induce nuclear translocation of p65/RelA as 
shown by immunofluorescence (Figure 3A) and immunoblotting of nuclear extracts 
(Figure 3B), although HIF-1proteins levels were stabilized under these conditions 
(see Figure 1B). Consistent with these results, the mRNA levels of the NF-B target 
genes Tnfa, Il6 and Cox2 were not induced in MC-38 cells exposed to hypoxia, but 
rather showed a small albeit not significant negative trend (Figure 3C). In conclusion, 
direct hypoxic induction of the NF-B signalling pathway does not appear to be a 
general phenomenon in carcinoma cells. 
 
Hif1a is not a transcriptional target of NF-B in MC-38 colon cancer cells 
Several previous reports demonstrated that NF-B binds to the promoter of the 
HIF1a gene and activates its transcription in a limited number of cell types (296-299). 
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However, no change in HIF-1 mRNA (Figure 4A) or protein (Figure 4B) levels could 
be detected in MC-38 cells treated with LPS, regardless of the oxygen concentration. 
These results were confirmed by the absence of any change in the mRNA levels of 
the canonical HIF target genes Glut1, Ca9 and Phd3 (compare Figures. 1C and 4C).  
 
Knock-down of p65/RelA does not affect HIF signalling  
To investigate whether NF-B could be involved in baseline rather than in conditional 
HIF-1 regulation, p65/RelA was knocked-down by RNA interference. MC-38 cells 
were stably transfected with a shRNA construct targeting p65/RelA, leading to an 
efficient decrease in p65/RelA mRNA (Figure 5A) and protein (Figure 5B) levels. 
However, knock-down of p65/RelA neither affected HIF-1 mRNA (Figure 5A) nor 
protein (Figure 5B) levels. These results were further corroborated by mRNA 
quantification of the HIF target genes Glut1, Ca9 and Phd3 which remained 
unaffected by p65/RelA knock-down under normoxic as well as hypoxic conditions 
(Figure 5C). 
 
Knock-down of HIF-1 does not affect NF-B signalling 
To investigate the converse possibility, that HIF-1 is involved in baseline rather than 
conditional NF-B regulation, HIF-1 was knocked-down by stable shRNA 
transfection. Because another retroviral vector backbone was used, two different 
shMOCK controls were generated, termed shMOCK_A (Figure 6) and shMOCK_B 
(Figure 5) for comparison with shHIF-1 and shp65/RelA, respectively. HIF-1 
knock-down efficiency was confirmed on the mRNA (Figure 6A) and protein (Figure 
6B) levels. However, HIF-1 knock-down neither affected p65/RelA mRNA levels 
(Figure 6A) nor total p65/RelA protein levels under normoxic as well as hypoxic 
conditions (Figure 6B). As shown in Figure 6C, also p65/RelA nuclear translocation 
following LPS treatment remained unaffected in HIF-1 knock-down MC-38 cells. 
These results were consistent with the mRNA regulation of the NF-B target genes 
Tnfa and Il6 which showed no significant difference following induction by LPS for 1 
to 8 hours (Figure 6D). 
  
  Results 
 
65 
 
Unexpected cross-talk between hypoxic and inflammatory pathways 
In order to obtain a comprehensive picture of the transcriptome regulation by the 
interaction between hypoxic and inflammatory pathways, MC-38 cells were further 
characterized by RNA deep sequencing. Therefore, the cells were cultured as small 
(approx. 250 m diameter) three-dimensional (3D) spheroids in hanging drops to 
more closely recapitulate solid tumour conditions. Of note, 3D spheroid conditions 
appeared to enhance the inflammatory response compared to conventional 2D sub-
confluent conditions in tissue culture plates. Following treatment with LPS, the TNF- 
mRNA induction rose from 7-fold in 2D to 21-fold in 3D (supplementary Figure S1A). 
Although we and others previously found hypoxic conditions in the core of larger 
tumour spheroids (301), HIF-1 remained largely unaffected in the relatively small 
MC-38 3D spheroid cultures (supplementary Figure S1B).  
 
Stable shHIF-1, shp65/RelA or shMOCK MC-38 cells were cultured in 3D for 48 
hours, exposed to 0.2% oxygen for 8 hours and treated with 1 g/ml LPS for the last 
1 hour of the hypoxic exposure. RNA deep sequencing and subsequent analysis was 
performed as described in the Materials and Methods section. Thresholds for 
induction and repression were chosen to be at least 1.5-fold or 0.67-fold, 
respectively. In the case of cells transfected with shHIF-1 or shp65/RelA, 
"repression" and "induction" in comparison with shMOCK-transfected cells refers to 
genes positively and negatively, respectively, regulated by HIF-1 and/or p65/RelA 
(supplementary Table S1).  
 
In summary, for the correct regulation of the majority of the hypoxically induced 
genes not only a functional HIF pathway (72%) but, unexpectedly, also a functional 
NF-B pathway (77%) was required. While regulation of 59% of the genes induced 
by the inflammatory stimulus was dependent on NF-B signalling, only 18% required 
the HIF pathway. Finally, the number of genes induced by LPS under normoxic 
conditions was reduced by almost 50% under hypoxic conditions, suggesting that 
hypoxia attenuates the inflammatory response of MC-38 cells. 
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Suppression of proinflammatory gene expression by HIF-1  
RNA sequencing revealed several mRNAs coding for proinflammatory proteins, 
including CCL20, CXCL5, CSF2 and TNF-, whose expression was repressed by 
HIF-1. Therefore, we validated the regulation of these genes by RT-qPCR analysis of 
independent experiments (Figure 7). Consistent with the RNA sequencing results, 
hypoxia attenuated the LPS-dependent stimulation of all above mentioned mRNAs in 
a HIF-1 dependent manner. 
 
Hypoxia impairs LPS-stimulated NF-B signalling by affecting the levels of  
IB  
Since nuclear translocation is the key event in NF-B activation, p65/RelA subcellular 
localization was analysed by immunofluorescence. Interestingly, while LPS strongly 
induced p65/RelA nuclear translocation (Figure 8A, left), this was blocked by 
simultaneous hypoxic exposure in HIF-1 wild-type as well as knock-down cells 
(Figure 8A, right). A similar result was obtained with 3D MC-38 cultures 
(supplementary Figure S2). To elucidate the mechanism of impaired p65/RelA 
nuclear translocation, p65/RelA translocation and IB levels were analysed in the 
same experiment (Figure 8B). A quantitative comparison of the number of cells with 
nuclear p65/RelA localization following LPS stimulation revealed an inverse 
association with IB. Consistent with the attenuated NF-B response, more cells 
were IB positive under hypoxic conditions (Figure 8C).  
 
DISCUSSION 
Mortality of colorectal cancer patients has been demonstrated previously to be 
associated with high HIF-1 but not HIF-2 levels (162, 302). The mouse model of 
colorectal cancer used in this study shows relevant features: HIF-2 mRNA levels in 
MC-38 colon adenocarcinoma cells were at least two orders of magnitude lower than 
the HIF-1 mRNA levels. Moreover, no HIF-2 protein could be detected under 
hypoxic conditions (data not shown) and the hypoxic response of the canonical HIF 
target genes Ca9 and Phd3 was almost fully abrogated in shHIF-1 cells, 
demonstrating the lack of redundancy of the HIF response in these cells 
(supplementary Figure S3). This finding is in line with a recent report demonstrating 
that the HIF2A/EPAS1 but not the HIF1A gene is epigenetically silenced in colonic 
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adenocarcinoma specimens when compared with non-neoplastic tissue (303). 
Therefore, shHIF-1 knock-down was sufficient to allow for the investigation of the 
role of the HIF signalling pathway in MC-38 cells.  
 
NF-B plays an important role during colorectal cancer progression and NF-B has 
been shown to be a prognostic factor negatively associated with survival in patients 
with metastatic colorectal cancer (214, 302) Colorectal cancer cells are likely to be 
exposed to bacterial LPS, derived from the gut microbiota, which is known to activate 
NF-B via Toll-like receptor (TLR) 4. Both TLR4 and its adapter MyD88 are increased 
in human sporadic colon cancer compared to surrounding normal and adenomatous 
epithelium, and they are associated with poor patient prognosis (256), suggesting 
that the LPS-TLR4-NF-B pathway plays a functional role in colon cancer. The 
epithelial MC-38 colon cancer cells used in this study robustly activated NF-B 
signalling in response to treatment with LPS, making them a suitable model to study 
the cross-talk between the hypoxic and the inflammatory pathways in colon cancer. 
 
Although MC-38 cells responded to LPS with nuclear p65/RelA translocation as well 
as NF-B target gene expression, no transcriptional induction of HIF-1 mRNA could 
be observed, although it was previously reported to occur in several other cellular 
systems (296-300). Even under 3D culture conditions, where we generally observed 
a stronger inflammatory response than in 2D cultures, no upregulation of HIF-1 
mRNA upon NF-B activation could be detected (data not shown). Similarly, four 
additional human colon cancer cell lines (COLO-741, HT-29, SW-620 and CX-1) 
showed no HIF-1 mRNA upregulation following LPS treatment (data not shown). In 
contrast, we observed a 6-fold upregulation of HIF-1 mRNA in primary mouse 
peritoneal macrophages following LPS stimulation (supplementary Figure S4), 
strongly suggesting that transcriptional HIF-1 regulation by NF-B is a cell type-
specific phenomenon. However, the additionally required factors that confer HIF-1 
induction by NF-B are currently unknown. 
 
In contrast to several previous reports suggesting hypoxic NF-B induction, (290, 
291, 293, 294) we found no increase in NF-B activity upon acute (up to 4 hours) or 
chronic (up to 72 hours) hypoxic exposure of MC-38 cells. Of note, only four of 32 
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different cancer cell lines have been shown to sustainably upregulate NF-B activity 
during a prolonged (48 hours) exposure to hypoxia, and this effect required the HPV-
encoded E6 protein. Just a few HPV-negative cell lines showed a moderate and 
transient (up to 3 hours) induction of NF-B activity upon exposure to hypoxia (292). 
PHD oxygen sensing enzymes have been shown to be both positively and negatively 
implicated in NF-B activation. PHD1 negatively regulates IB kinase- in HeLa cells, 
and PHD3 is a negative regulator of NF-B in skeletal myoblast differentiation (291, 
304). On the other hand, LPS-induced cytokine expression in macrophages was 
suppressed by treatment with the PHD inhibitor dimethyloxalylglycine or siRNA-
mediated knockdown of PHD1 and PHD2 (305). 
 
Rather than inducing NF-B, however, hypoxia attenuated the proinflammatory 
response to LPS in MC-38 cells cultured under 2D and 3D conditions. RNA deep 
sequencing revealed a role for HIF-1 in the decreased hypoxic induction of some 
but not of all NF-B target genes. A direct repressive HIF function is unlikely because 
genome-wide DNA association studies combined with transcriptional profiling and 
assessment of histone marks clearly revealed a transcriptional enhancer but no 
repressor function of both HIF-1 and HIF-2(306). Quite unexpectedly, hypoxia 
inhibited the LPS-mediated decrease in IBlevels in a HIF-independent manner, 
resulting in decreased p65/RelA nuclear translocation. While these findings, at least 
partially explain the attenuated inflammatory response, we currently do have no 
explanation how hypoxia influences IB. It has recently been suggested that 
inhibition of the oxygen-dependent PHD1 or FIH protein hydroxylases blocks distal 
IL-1 signalling components of the TRAF6 complex involved in NF-B activation 
(307). Whether similar mechanisms are involved in the hypoxic attenuation of the 
LPS response needs to be investigated. 
 
Both, the hypoxic and the inflammatory pathways are increasingly being recognized 
for cancer diagnosis as well as for tumour therapy (284). Our results demonstrate a 
complex interplay between these two pathways in colon cancer cells. Whereas direct 
transcriptional cross-talks between HIF-1 and p65/RelA could not be confirmed in 
this cell type, strong indirect interactions between the two pathways could be 
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demonstrated, suggesting that these two microenvironmental stimuli should always 
be considered simultaneously when designing novel approaches to tumour therapy. 
 
MATERIALS AND METHODS 
Cell culture 
Mouse colon adenocarcinoma MC-38 GFP (if not indicated otherwise, hereafter 
referred to as "MC-38") cells (308) were cultured in high glucose DMEM medium 
(Sigma, St. Louis, MO, USA; or Gibco, Carlsbad, CA, USA) supplemented with 10% 
FCS (Gibco), 50 IU/ml penicillin and 100 g/ml streptomycin. MC-38 3D spheroid 
cultures were grown in hanging drops in 60-well microtest plates (Greiner, 
Frickenhausen, Germany) by seeding 2500 cells/25 l drop 48 hours before the 
experiment. For hypoxia experiments, cells were grown in a gas-controlled 
workstation (InvivO2 400, Ruskinn Technologies, Pencoed, UK). For inflammatory 
stimulation, MC-38 cells were treated with 1 g/ml LPS derived from E.coli (Sigma).  
 
mRNA quantification 
Total cellular RNA was extracted as described(309) or by using the Nucleospin RNA 
II extraction kit (Macherey-Nagel, Düren, Germany). cDNA was synthesized from 1-2 
g of total RNA using Affinity Script reverse transcriptase (RT) (Agilent Technologies, 
Santa Clara, CA, USA). Quantitative (q) PCR was performed using SybrGreen 
master mix (Sigma) on a MX3000P light cycler (Agilent Technologies). Primers were 
purchased from Mycrosynth (Balgach, Switzerland) and are listed in supplementary 
Table S2. RNA sample quality and equal inputs were assessed by RT-qPCR 
quantification of ribosomal protein S12 mRNA, and all data were expressed as ratios 
over S12 mRNA.  
 
Protein extraction and immunoblotting 
Cells were washed twice with ice-cold PBS by centrifugation for 3 minutes at 1200 
rpm. For total protein extraction, cells were resuspended in lysis buffer (10 mM Tris-
HCl pH 8.0, 1 mM EDTA, 400 mM NaCl, 0.1% NP-40, freshly added 1 mM PMSF 
and Sigma's Protease Inhibitor Cocktail). For nuclear protein extraction, cells were 
resuspended in hypotonic buffer (10 mM HEPES/KOH pH 7.9, 10 mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA with freshly added 1 mM PMSF). After 15 minutes on ice, NP-
40 was added to a final concentration of 0.1% and the samples were immediately 
  Results 
 
70 
 
vortexed for 20 seconds. Nuclei were pelleted for 30 seconds at 5000 rpm, washed 
with hypotonic buffer and extracted on ice in hypertonic extraction buffer (20 mM 
HEPES/KOH pH 7.9, 400 mM NaCl, 1mM EDTA, 1mM EGTA and protease 
inhibitors) for 10 minutes. Proteins were separated by 10% SDS-PAGE, 
electrotransferred to PVDF membranes and detected using anti-p65/RelA (Santa 
Cruz Biotechnology, Dallas, TX, USA), anti-HIF-1 (Novus Biologicals, Littletone, 
CO, USA), anti-HDAC1 (Abcam, Cambridge, UK), anti-SP1 (Santa Cruz 
Biotechnology) or anti--actin (Sigma) antibodies. 
 
Immunofluorescence microscopy 
Following fixation with 4% paraformaldehyde for 30 minutes at room temperature, 
MC-38 cells were washed twice with PBS, permeabilized with 0.1% saponin, free 
aldehyde groups quenched with 20 mM glycine, and unspecific binding sites blocked 
with 10% FCS for 30 minutes. Proteins were detected by incubation for 1 hour at 
37°C with anti-p65/RelA (Santa Cruz Biotechnology) or anti-IB (Cell Signalling 
Technology, Denvers, MA, USA) antibodies. After washing with PBS, the respective 
secondary antibodies labelled with Cy3 (Jackson Immunoresearch, West Grove, PA, 
USA), Alexa488 or Alexa568 (Molecular Probes, Carlsbad, CA, USA) were applied, 
and nuclei were counter-stained with DAPI. Samples were mounted using Mowiol 
(Millipore, Darmstadt, Germany) and analysed by fluorescence microscopy. 
Spheroids were fixed in 10% formalin for 30 minutes at room temperature and 
processed for histological analysis using previously described techniques.(310) 
Dewaxed paraffin sections (5 m) were rehydrated, blocked with 10% normal goat 
serum and processed as described above.  
 
RNA interference 
Knock-down of specific mRNAs was achieved by lentiviral transduction of short 
hairpin RNA (shRNA) vectors driven by the U6 promoter in the pLKO.1-puro plasmid 
(Sigma). Vectors targeting mouse HIF-1 (shHIF1) and non-target controls 
(shMOCK_A) were purchased from Sigma. To construct the shp65 vector, the 
oligonucleotides 5'-gatccccagggcaaactgtagagtcattcaagagatgactctacagtttgcccttttttggaaa-3' 
and 5'-agcttttccaaaaaagggcaaactgtagagtcatctcttgaatgactctacagtttgccctggg-3' were annealed, 
phosphorylated and ligated into the pSUPER vector. A BamHI/SalI fragment of the 
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H1-RNA promoter was ligated into the pRDI292 vector (kind gift from P. O. Hassa, 
Zurich, Switzerland) and used for expression of shp65. 
 
RNA sequencing 
RNA was extracted and pooled from 3 independent 3D-cultures grown under hypoxic 
or normoxic conditions. Ribosomal RNA in the pooled RNA was depleted using 
Encore Complete RNA-Seq Library Systems (NuGEN, San Carlos, CA, USA) and 
RNA was sequenced using an Illumina HiSeq 2000 sequencer (San Diego, CA, USA) 
at the Functional Genomics Center Zurich. Isoform and gene expression levels were 
computed with RSEM (Version 1.2.0; http://www.biomedcentral.com/1471-
2105/12/323). RSEM was run in stranded mode with the additional option to estimate 
the distribution of the read start positions. The expression levels (RSEM's posterior 
estimate of the read counts per transcript normalized for gene length) were 
normalized across samples using the geometric mean of all expression signals. To 
attenuate expression ratios for low abundance genes, a fixed value of 5 was added 
to all expression values before computing the log-ratio. Threshold levels for hypoxia-
or LPS-dependent up- or downregulation were set at >1.5 or <0.67, respectively, as 
were the threshold levels for HIF-1 or p65/RelA dependency of up- or down-
regulated gene expression when compared to the respective shMOCK controls. Only 
genes with a minimal expression level of 10 were considered biologically relevant. 
 
Statistical analysis 
Unless indicated otherwise, all experiments were repeated at least three times 
independently. Data are shown as mean values ± SD. Student's t-tests were applied 
to analyse the data with a p-value < 0.05 considered to be statistically significant. 
 
CONFLICT OF INTEREST 
The authors declare no conflict of interest. 
 
ACKNOWLEDGEMENTS 
This work was supported by the Swiss National Science Foundation (grants 
PDFMP3_127315 and 31003A_146203) and the KFSP Tumour Oxygenation of the 
University of Zurich.  
 
  Results 
 
72 
 
SUPPLEMENTARY INFORMATION 
Supplementary Information accompanies the paper on the Oncogene website 
(http://www.nature.com/onc).  
 
FIGURE LEGENDS 
 
Figure 1. Hypoxic response of MC-38 cells. (A) Time-dependent RT-qPCR 
quantification of HIF-1 and HIF-2 mRNA levels following exposure to hypoxia as 
indicated. (B) Kinetics of hypoxic HIF-1 protein accumulation analysed by 
immunoblotting of 50 g total protein extracts. (C) Kinetics of hypoxic induction of 
canonical HIF target genes quantified by RT-qPCR of GLUT-1, CAIX and PHD3 
mRNA. Shown are mean values ± SD of mRNA ratios relative to the constitutively 
expressed ribosomal protein S12 mRNA levels of n = 3 independent experiments; *, 
p < 0.05; **, p < 0.01; ***, p < 0.001 (Student's t-test). 
 
Figure 2. Inflammatory response of MC-38 cells. (A) Immunofluorescence 
microscopy of p65/RelA in MC-38 cells following treatment with 1 g/ml LPS for 40 
minutes. (B) Immunoblot detection of p65/RelA and HDAC1 in nuclear extracts 
derived from MC-38 cells following stimulation with 1 g/ml LPS for 1 hour (n = 2 
independent experiments). (C) Kinetics of inflammatory induction (1 g/ml LPS for 
the time periods indicated) of canonical NF-B target genes quantified by RT-qPCR 
of TNF-, IL-6 and COX-2 mRNA. Shown are mean values ± SD of mRNA ratios 
relative to the constitutively expressed ribosomal protein S12 mRNA levels of n = 3 to 
4 independent experiments; **, p < 0.01 (Student's t-test).  
 
Figure 3. NF-B signalling under hypoxic conditions. (A) Immunofluorescence 
microscopy of p65/RelA in MC-38 cells following exposure to 0.2% oxygen for 0.5 to 
4 hours. Treatment with 1 g/ml LPS for 1 hour served as positive control. (B) 
Immunoblot detection p65/RelA and the constitutive Sp1 transcription factors in MC-
38 nuclear extracts following exposure to 1 g/ml LPS or 0.2% oxygen for 1 to 12 
hours. (C) RT-qPCR analysis of the regulation of the canonical NF-B target genes 
Tnfa, Il6 and Cox2 following hypoxic exposure. 
 
Figure 4. HIF signalling under inflammatory conditions. (A) RT-qPCR analysis of the 
HIF-1 mRNA response to LPS treatment in MC-38 cells. (B) Kinetics of the HIF-1 
protein response to LPS and/or hypoxia as assessed by immunoblotting of 50 g 
total cell extracts. -Actin served as loading control. (C) RT-qPCR analysis of the 
effects of LPS treatment on the canonical HIF targets gene Glut1, Ca9 and Phd3. 
 
Figure 5. HIF signalling in p65/RelA knock-down cells. (A) RT-qPCR analysis of HIF-
1 and p65/RelA mRNA in MC-38 cells stably transfected with shp65/RelA or 
shMOCK_B negative control constructs. (B) Immunoblotting of HIF-1 and p65/RelA 
protein after 8 to 72 hours of hypoxic exposure of shMOCK_B or shp65/RelA MC-38 
cells. -Actin served as loading control. (C) RT-qPCR analysis of the canonical HIF 
target genes Glut1, Ca9 and Phd3 in shMOCK_B or shp65/RelA MC-38 cells cultured 
under normoxic or hypoxic conditions as indicated. 
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Figure 6. p65/RelA signalling in HIF-1 knock-down cells. (A) RT-qPCR analysis of 
HIF-1 and p65/RelA mRNA in MC-38 cells stably transfected with shHIF1 or 
shMOCK_A control constructs. (B) Immunoblotting of HIF-1 and p65/RelA protein 
after 8 hours of hypoxic exposure of shMOCK_A or shHIF1 MC-38 cells. -Actin 
served as loading control. (C) Immunofluorescence microscopy of p65/RelA in 
shMOCK_A or shHIF-1 MC-38 cells treated with 1 g/ml LPS for 40 minutes. (D) 
RT-qPCR analysis of the canonical NF-B target genes Tnfa and Il6 in shMOCK_A 
or shHIF-1 MC-38 cells upon treatment with LPS for 1 to 8 hours.  
 
Figure 7. Validation of the RNA sequencing data. MC-38 cells were grown as 
spheroids in hanging drop cultures for 48 hours before exposure to hypoxia (0.2% 
oxygen) for 8 hours and treatment with 1 g/ml LPS for the last 1 hour of normoxic or 
hypoxic cell culture. CCL20, CXCL5, CSF2 and TNF- mRNA levels were quantified 
by RT-qPCR. Shown are mean values normalized to the mean of each experiment ± 
SD of mRNA ratios relative to the constitutively expressed ribosomal protein S12 
mRNA levels of n = 3 to 4 independent experiments. Student's t-test were performed 
to evaluate the effects of hypoxia on LPS stimulation: *, p < 0.05; **, p < 0.01; ***, p < 
0.001.  
 
Figure 8. Inverse regulation of NF-B and IB under hypoxic conditions. (A) 
Immunofluorescence microscopy of p65/RelA in shMOCK_A and shHIF-1 MC-38 
cells following exposure to 0.2% oxygen for 8 hours and/or 1 g/ml LPS for the last 
40 minutes before harvesting. (B) Immunofluorescence microscopy of IB and 
p65/RelA in MC-38 cells (without GFP) exposed to 0.2% oxygen for 8 hours and/or 1 
g/ml LPS for the last 30 minutes before harvesting. (C) For fractional quantification 
of the results shown in (B), at least 200 cells of each experiment were classified 
according to the subcellular localization of p65/RelA and the expression of IB was 
quantified with use of ImageJ. 
 
SUPPLEMENTARY INFORMATION 
 
Table S1. Gene regulation revealed by RNA sequencing. 
 
Table S2. Primers used for real-time PCR. 
 
Figure S1. Spheroid cultures of MC-38 colon carcinoma cells. MC-38 cell were either 
cultured as sub-confluent two-dimensional monolayers in tissue culture plates ("2D") 
or as three-dimensional spheroids in hanging drops ("3D") for 48 hours before the 
experiment was started. (A) Both 2D and 3D cultures were stimulated with 1 g/ml 
LPS for 1 hour and the TNF- mRNA levels were determined by RT-qPCR. (B) Cells 
were exposed to hypoxia (3% or 0.2% O2) for 8 hours and/or 1 g/ml LPS for the last 
2 hours before harvesting. HIF-1 protein was detected by immunoblotting of 50 g 
of total protein extracts. -Actin served as loading control.  
 
Figure S2. Nuclear translocation of p65/RelA in hypoxic spheroid cultures. 
Immunofluorescence microscopy of p65/RelA in MC-38 cells grown as spheroids in 
hanging drop cultures for 48 hours before exposure to hypoxia (0.2% oxygen) for 8 
hours and/or 1 g/ml LPS for the last 40 minutes before harvesting.  
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Figure S3. CAIX and PHD3 mRNA levels in shHIF-1 MC-38 cells. Hypoxic 
induction of the canonical HIF target genes Ca9 and Phd3 was quantified by RT-
qPCR. Shown are mean values ± SD of mRNA ratios relative to the constitutively 
expressed ribosomal protein S12 mRNA levels of n = 3 to 4 independent 
experiments. 
 
Figure S4. Inflammatory response of macrophages. Transcript levels of TNF- and 
HIF-1 were determined by RT-qPCR in mouse primary peritoneal macrophages 
following stimulation with 100 ng/ml LPS for 8 hours. 
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                      Tab. S1 
 
                      Gene regulation revealed by RNA sequencing  
 
                              Conditions  +Hyp/-LPS +Hyp/+LPS -Hyp/+LPS +Hyp/+LPS  
            vs.        vs.        vs.        vs.  
  -Hyp/-LPS -Hyp/-LPS -Hyp/-LPS +Hyp/-LPS 
 
                             upregulated genes (total)   924 645 277  141  
 
                             regulated by: 
                             HIF-1 (+)  663 393 45  26 
                             HIF-1 (-)  1 7 6    9 
                             HIF-1 (total)  664 400 51  35 
                             p65/RelA (+)  708 135 164  34 
                             p65/RelA (-)  2 4 0    4 
                             p65/RelA (total)  710 139 164  38 
                             HIF-1 (+), p65/RelA (+)  538 77 31  11 
                             HIF-1 (-), p65/RelA (-)  0 0 0    1 
                             HIF-1 (+), p65/RelA (-)  1 4 0    0 
                             HIF-1 (-), p65/RelA (+)  0 4 2    5 
                             HIF-1 and p65/RelA (total)  539 85 33  17 
 
                             downregulated genes (total)   429 332 36  105  
 
                             regulated by: 
                             HIF-1 (+)  12 12 0    2 
                             HIF-1 (-)  106 78 17  53 
                             HIF-1 (total)  118 90 17  55 
                             p65/RelA (+)  155 10 0    2 
                             p65/RelA (-)  50 60 21  76 
                             p65/RelA (total)  205 70 21  78 
                             HIF-1 (+), p65/RelA (+)  6 3 0    0 
                             HIF-1 (-), p65/RelA (-)  16 35 9  36 
                             HIF-1 (+), p65/RelA (-)  0 0 0    2 
                             HIF-1 (-), p65/RelA (+)  32 0 0    1 
                             HIF-1 and p65/RelA (total)  54 38 9  39 
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Tab. S2 
Primers used for real-time PCR 
mRNA  forward primer reverse primer 
 
CAIX  carbonic anhydrase 9   5’-gctgtcccatttggaagaaa-3’ 5’-ggaaggaagcctcaatcgtt-3’ 
CCL20  chemokine (C-C motif) ligand 20 5’-cgactgttgcctctcgtaca-3’ 5’-gaggaggttcacagcccttt-3’ 
COX-2 cytochrome oxidase 2 5’-tcctcctggaacatggactc-3’ 5’-ccccaaagatagcatctgga-3’ 
CSF2 colony stimulating factor 2 5’-acatgcctgtcacgttgaat-3’ 5’-ttgagtttggtgaaattgcc-3’ 
CXCL5 chemokine (C-X-C motif) ligand 5 5’-gctgctgtgtcatgcagaaaccta-3’ 5’-gacattatgccatactacgaagacatc-3’ 
GLUT-1 glucose transporter 1 5’-tctctgtcggcctctttgtt-3’ 5’-gcagaagggcaacaggatac-3’ 
HIF-1 hypoxia-inducible factor 1 5’-acaagtcaccacaggacag-3’ 5’-agggagaaaatcaagtcg-3’ 
HIF-2 hypoxia-inducible factor 2 5’-taaagcggcagctggagtat-3’ 5’-actgggaggcatagcactgt-3’
IL-6 interleukin 6 5’-tcctctctgcaagagacttccatcc-3’ 5’-aagcctccgacttgtgaagtggt-3’
p65/RelA NF-B subunit p65 5’-gcgtacacattctggggagt-3’ 5’-accgaagcaggagctatcaa-3’ 
PHD3 prolyl-4-hydroxylase domain protein 3 5’-caacttcctcctgtccctca-3’ 5’-ggctggacttcatgtggatt-3’ 
S12 ribosomal protein S12 5’-gaagctgccaaagccttaga-3’ 5’-aactgcaaccaaccaccttc-3’ 
TNF- tumour necrosis factor  5’-gtcgtagcaaaccaccaagtgg-3’ 5’-gagatagcaaatcggctgacgg-3’ 
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6.2. Additional unpublished data 
 
RESULTS 
Expression of HIF-1 mRNA following LPS exposure is independent on DNA 
methylation in MC-38 cells 
Our previous data revealed no transcriptional regulation of Hif1a in MC-38 cells, 
following NF-B activating LPS treatment (see chapter 6.1.). However, binding of NF-
B to DNA can be inhibited in a methylation-dependent manner (311, 312). In 
addition, methylation of Hif1a gene was shown to be involved in regulation of HIF-1 
expression in colon cancer cells (313). Therefore, MC-38 cells were treated with DNA 
demethylating agent 5-aza-2´-deoxycytidine (5-aza-2´-dC), to test the possible 
methylation of B site in Hif1a gene as a reason for lack of NF-B-mediated 
transcriptional HIF-1 upregulation in those cells. Neither the LPS treatment of 
conventional two-dimensional (2D) cultures, nor of spheroid 3D cultures (hanging 
drops) of MC-38 cells preexposed to 5-aza-2´-dC, affected the levels of HIF-1 
transcript (FIG.1A-B). Importantly, mRNA levels of amphiregulin (AREG), whose 
expression was previously shown to be regulated by DNA methylation (314), was 
increased in cells treated with 5-aza-2´-dC. AREG transcript upregulation reached 
7.1- and 4-fold in 2D and 3D, respectively (compare LPS- and 5-aza-2´-dC-untreated 
cells to LPS-untreated and 0.35 M 5-aza-2´-dC-treated), indicating efficient DNA 
demethylation upon treatment of MC-38 cells with 5-aza-2´-dC (Figure 1A-B). 
Simultaneously, stimulation with LPS upregulated a known NF-B target gene Tnfa 
expression in 2D as well as in 3D MC-38 cell cultures, indicating that NF-B pathway 
was induced in these experimental conditions (Figure 1A-B). Despite induction of 
AREG mRNA expression (demethylation treatment positive control) and induction of 
TNF- (LPS treatment positive control) the levels of HIF-1 transcript remained 
unaltered following the exposure of cells to proinflammatory treatment, excluding 
inhibitory effect of methylation of B site in Hif1a locus as a reason for lack of its 
transcriptional regulation by NF-B in MC-38 cells.  
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Knock-down of p65/RelA does not influence HIF-1 protein accumulation in 
hypoxic MC-38 cells 
To confirm our previous findings on no effect of p65/RelA knock-down on HIF-1 
accumulation in hypoxia (see chapter 6.1.), two independent shRNA-mediated 
p65/RelA knock-downs in MC-38 cells were established. Accumulation of HIF-1 
protein in hypoxia, in both shp65/RelA#1 and shp65/RelA#2 MC-38 cell lines 
remained unaltered compared to shMOCK_A control cells (Figure 2). Expression of 
HIF-1 protein in hypoxia is independent of the basal expression levels of p65/RelA 
in MC-38 cells.  
 
shRNA-mediated knock-down of HIF-1 in MC-38 cells grown in 3D cultures 
displays a robust decrease in HIF-1 expression 
To confirm the high efficiency of stable HIF-1 knock-down in MC-38 cells in 3D 
spheroid cell culture conditions, shHIF-1, shp65/RelA and shMOCK control cell 
lines (see Chapter 6.1.) were cultivated in 3D hanging drops for 48 h, followed by the 
exposure to hypoxia and/or LPS. Efficient knock-down of HIF-1 in shHIF-1 
compared to shMOCK_A cells could be confirmed on the mRNA level (81% reduction 
in LPS-untreated in normoxia). Furthermore, HIF-1 transcript abundance was 
unaffected by shp65/RelA expression in MC-38 cells (Figure 3A). Knock-down of 
HIF-1 could be further evidenced on the protein levels in shHIF-1 MC-38 cells 
grown as for Figure 3A and subsequently exposed to hypoxia or the PHD enzyme 
inhibitor DMOG (Figure 3B). 
 
shRNA-mediated knock-down of p65/RelA in MC-38 cells grown in 3D cultures 
displays a robust decrease in p65/RelA expression 
To confirm the high efficiency of stable p65/RelA knock-down in MC-38 cells in 3D 
spheroid culture conditions, shp65/RelA, shHIF-1 and shMOCK control cell lines 
(see Chapter 6.1.) were cultivated and treated as for Figure 3A. Efficient knock-down 
of p65/RelA in shp65/RelA compared to shMOCK_B cells could be confirmed on the 
mRNA levels (64% reduction in LPS-untreated in normoxia). Moreover, p65/RelA 
transcript abundance was unaffected by shHIF-1 expression in MC-38 cells (Figure 
4A). Knock-down of p65/RelA could be also shown on the protein levels in 
shp65/RelA MC-38 cells grown and treated as for Figure 3A (Figure 4B). 
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LPS-mediated response is attenuated by HIF-1 in conventional 2D MC-38 cell 
cultures 
Our previous results, showed that the response to treatment with LPS under hypoxia 
is decreased compared to normal oxygen conditions in 3D spheroid cultures of MC-
38 cells (see chapter 6.1.). For a subset of well known NF-B target genes including 
Ccl20, Cxcl5, Csf2 and Tnfa, HIF-1 was found to be a negative regulator of their 
LPS-mediated induction (see chapter 6.1.). To confirm these findings in conventional 
2D cultures, shMOCK_A and shHIF-1 MC-38 cells were exposed to hypoxia and/or 
LPS. CXCL5, CSF2 and TNF- mRNA levels in control shMOCK_A cells were 4.6-, 
1.9-, 2.9-, respectively, higher following the LPS treatment in normoxia than in 
hypoxia. However, CCL20 mRNA displayed no hypoxic effect on its LPS-response 
inducibility. In the case of CXCL5, CSF2 and TNF-transcripts, HIF-1 knock-down 
at least partially rescued the hypoxic repression of their response to LPS treatment. 
Interestingly, HIF-1 knock-down cells showed increased CCL20 mRNA response to 
LPS compared to control cells irrespective of the oxygen conditions. The LPS-
induced increase in CCL20 transcript abundance in shHIF-1 compared to 
shMOCK_A cells reached 2.4- and 4.2-fold in normoxia and hypoxia, respectively. A 
summary of these findings is displayed in the Figure 5. 
 
DISCUSSION 
Direct regulation of HIF-1 mRNA expression by NF-B has been described before 
in several models including different macrophage cell lines and primary human 
macrophages, as well as human embryonic kidney (HEK) 293, and pulmonary artery 
smooth muscle cells (PASMCs) (264-268). Furthermore, in the absence of functional 
NF-B pathway, hypoxic activation of HIF-1 expression in bone marrow-derived 
macrophages (BMDMs) as well as livers and brains of mice was decreased (263). 
However, our previous data indicated no transcriptional regulation of HIF-1 mRNA 
expression in MC-38 cells stimulated with LPS despite robust concomitant NF-B 
activation. Consistently, we could not observe attenuated hypoxic HIF-1 activation 
in p65/RelA knock-down MC-38 cells (see chapter 6.1.). As one of the possible 
mechanisms why this process may be limited only to particular cells, methylation of 
the B site in the Hif1a gene was considered. Methylation of the NF-B binding DNA 
sites was previously suggested to be involved in the regulation of the expression of 
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known NF-B target gene iNOS as well as binding of NF-B to cognate motifs in HIV-
1 long terminal repeats (311, 312). In addition, HIF-1 transcription induction in 
hypoxia has been shown to be dependent on the lack of HRE methylation and 
therefore autoregulatory HIF-1 binding in colon cancer cell lines, indicating the 
involvement of DNA methylation in the HIF-1 mRNA expression (313). To test the 
possible inhibitory effect of methylation of B site on the NF-B binding to Hif1a 
promoter and therefore attenuation of NF-B-mediated HIF-1 induction in MC-38 
cells, the treatment with demethylating agent 5-aza-2´-deoxycytidine (5-aza-2`-dC) 
was applied. One of the mechanisms by which 5-aza-2`-dC mediates DNA 
demethylation is its incorporation to DNA and subsequent covalent binding-mediated 
inactivation of the DNA methyltransferases (315, 316). However, the pretreatment of 
MC-38 cells with 5-aza-2`-dC did not result in the increase in HIF-1 transcript 
abundance following the proinflammatory stimulation, ruling out methylation of the B 
site in Hif1a promoter as a mechanism of lack of NF-B-mediated HIF-1 induction in 
MC-38 cells. In agreement with no LPS-mediated regulation of HIF-1 transcription in 
MC-38 cells, we previously showed no alterations in hypoxic HIF-1 protein 
accumulation in cells expressing stable shRNA targeting p65/RelA (see chapter 6.1.). 
In the current work, these findings were confirmed in two independent shp65/RelA 
MC-38 cell lines, further supporting no dependence of HIF-1 expression on NF-B 
in MC-38 cells. The direct regulation of HIF-1 mRNA following the proinflammatory 
treatment remains a compelling target to study the interplay between hypoxia and 
inflammation. The transcriptional induction of HIF-1 by NF-B appears to be cell 
type specific. Among proposed mechanisms of the specificity of NF-B-mediated 
transcription activation in distinct cell types is differential recruitment of transcriptional 
cofactors e.g. MYB-binding protein 1A (MYBBP1A) and downregulated in metastasis 
(DRIM), both enriched in complexes with TAD domain of p65/RelA in nuclear extracts 
from Jurkat cells, IQ motif containing GTPase activating protein 3 (IQGAP3) in THP-
1, or human general control of amino acid synthesis 1-like 1 (hGCN1L1) in HeLa 
(317). However, the factors responsible for cell-type specific regulation of HIF-1 
transcript abundance following activation of NF-B are currently unknown. 
 
Our previous data suggested that hypoxia attenuates the cellular response to LPS, 
and that HIF-1 is a negative regulator of a panel of known NF-B target genes 
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Ccl20, Cxcl5, Csf2 and Tnfainvolved in the recruitment and activation of leucocytes 
(see chapter 6.1.). Mentioned results were obtained in MC-38 cells grown in 3D 
spheroid cultures, which display more robust activation following proinflammatory 
stimulation with LPS compared to cells cultivated in commonly applied 2D cell growth 
conditions in tissue culture dishes (see chapter 6.1.). In the current work, the findings 
on the negative regulation of LPS-stimulated expression of CCL20, CXCL5, CSF-2 
and TNF-mRNAs by HIF-1could also be confirmed in 2D cell cultures, suggesting 
that this effect is not restricted to hanging drop MC-38 cultures.  
 
It was previously shown that hypoxia and in particular HIF-1 is involved in the 
CD45+ myeloid cell recruitment from the bone marrow in glioblastoma, an effect at 
least partially dependent on HIF-1-dependent induction of CXCL12 chemokine (also 
known as stromal cell-derived factor 1 - SDF-1) (140). However, by attenuation of the 
LPS-mediated upregulation of CCL20, CXCL5, CSF-2 and TNF-expression HIF-1 
may possibly play another context-dependent role, in regulating the inflammatory 
component in the colon cancer. Follow-up studies should aim at verifying the 
inhibitory role of HIF-1 on the expression of those inflammatory mediators in mouse 
colon tumors, as well as the downstream effects of this interaction axis on the 
inflammatory composition of tumor microenvironment.  
 
MATERIALS AND METHODS 
5-aza-2´-deoxycytidine (5-aza-2´-dC) was purchased from Sigma (St. Louis, MO, 
USA). Knock-down of specific mRNAs was achieved by lentiviral transduction of 
short hairpin RNA (shRNA) vectors driven by the U6 promoter in the pLKO.1-puro 
plasmid (Sigma). Vectors targeting mouse p65/RelA (shp65/RelA#1 and 
shp65/RelA#2) and non-target controls (shMOCK_A) were purchased from Sigma. 
Primers used for RT-qPCR were: mouse-actin forward 5’-gagcgtggctacagcttcac-3’ 
and reverse 5’-ggcatagaggtctttacggatg-3’ and mouse AREG forward 5’-
gactcacagcgaggatgaca-3’ and reverse 5’-ggcttggcaatgattcaact-3’. Remaining 
materials and methods were described in the chapter 6.1. 
FIGURE LEGENDS 
Figure 1. 5-aza-2´-dC treatment of MC-38 cells. RT-qPCR analysis of the abundance 
of AREG, TNF- and HIF-1 transcripts in MC-38 cells pretreated with 0.25 or 0.35 
M 5-aza-2´-dC for 96 h. (A) Cells were starved for 16 h in medium containing 0.1 % 
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FCS, followed by the exposure to 1 g/ml LPS for 1 h. (B) Cells were cultivated in 3D 
spheroids for 24 h, followed by the stimulation with 1 g/ml LPS for 1 h. Data were 
normalized to the constitutively expressed -actin mRNA levels.  
 
Figure 2. Hypoxic HIF-1 accumulation in cells stably expressing shRNA targeting 
p65/RelA in MC-38 cells. Immunoblot detection of HIF-1 and p65/RelA in 50 g of 
total extracts derived from stable shRNA-mediated knock-down shp65/RelA#1, 
shp65/RelA#2, shHIF-1 and control shMOCK_A MC-38 cell lines exposed to 
hypoxia (0.2 % oxygen) for 8 h. -actin served as a loading control.  
 
Figure 3. Stable shRNA-mediated HIF-1knock-down in MC-38 cells cultured in 3D 
spheroids. shHIF-1 and shMOCK_A, as well as shp65/RelA and shMOCK_B MC-38 
cells were grown for 48 h in 3D spheroid cultures and exposed to hypoxia (0.2% 
oxygen) or 1 mM DMOG for 8 h, followed by the treatment with 1 g/ml LPS for the 
last 1 h of hypoxic/DMOG cell cultures. (A) HIF-1 mRNA levels were quantified by 
RT-qPCR. Data were normalized to the constitutively expressed ribosomal protein 
S12 mRNA. (B) HIF-1 protein levels were analysed by immunoblotting of 50 g of 
total protein extracts. -actin served as loading control.  
 
Figure 4. Stable shRNA-mediated p65/RelA knock-down in MC-38 cells cultured in 
3D. shHIF-1 and shMOCK_A, as well as shp65/RelA and shMOCK_B MC-38 cells 
were grown for 48 h in 3D spheroid cultures and exposed to hypoxia (0.2% oxygen) 
for 8 h, followed by the treatment with LPS for  the last 1 h of hypoxic or normoxic cell 
cultures. (A) p65/RelA mRNA levels were quantified by RT-qPCR. Data were 
normalized to the constitutively expressed ribosomal protein S12 mRNA. (B) 
p65/RelA protein levels were analysed by immunoblotting of 50 g total protein 
extracts. -actin served as loading control. 
 
Figure 5. The effect of HIF-1 on the expression of known NF-B target genes in 
MC-38 cultivated in conventional 2D cultures. CCL20, CXCL5, CSF2 and TNF- 
mRNA levels were quantified by RT-qPCR in 2D MC-38 cultures prestarved for 16 h 
in medium containing 0.1% FCS, exposed to hypoxia (0.2% oxygen) for 8 h and 
treated with 1 g/ml LPS for the last 1 h of hypoxic or normoxic exposure. Data were 
normalized to the constitutively expressed ribosomal protein S12 mRNA levels. 
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6.3. Personal contribution 
 
 Hypoxia attenuates the inflammatory response in colon cancer cells by 
affecting the levels of IB. Kamila Bartnicka1,2,6, Karolin Léger2,3,6, Jesus 
F. Glaus Garzon1,2, Carole Oertli1,2, Ali Mirsaidi2,3, Peter J. Richards4, 
Hubert Rehrauer5, Patrick Spielmann1,2, David Hoogewijs1,2, Lubor 
Borsig1,2,7, Michael Hottiger2,3,7, Roland H. Wenger1,2,7,*  
 
Concerning performing the experiments: 
Fig.1 – all 
Fig.2 – all, except 2A (equally contributed with KL) 
Fig.3 – all 
Fig.4 – all 
Fig.5 – all, except generating shp65/RelA MC-38 cells 
Fig.6 – all, except 6C (equally contributed with KL) 
Fig.7 – all but equally contributed with KL 
Fig.8 – 8A (equally contributed with KL), 8B (equally contributed with 
   PS), 8C – all 
Fig.S1 – all but equally contributed with KL 
Fig.S2 – all but equally contributed with KL and AM 
 Fig.S3 – all but equally contributed with KL 
Fig.S4 – all 
Tab.S1 – all but equally contributed with KL 
 
 Additional unpublished data. 
 
Concerning performing the experiments: 
Fig.1 – all 
Fig.2 – all 
Fig.3 – all but equally contributed with KL 
Fig.4 – all but equally contributed with KL 
Fig.5 – all 
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7. Conclusions 
Colorectal cancer (CRC) represents an interesting model to study the interplay 
between hypoxic and inflammatory pathways. It is an example of a malignancy with 
well established link to chronic inflammation, such as in inflammatory bowel disease 
(208, 209). CRCs are commonly characterized by the presence of hypoxia and 
inflammation, and activation of HIF-1 as well as NF-B in this type of malignancy 
implies worse patient prognosis (162, 214, 251, 258, 259).  
Mouse colon adenocarcinoma MC-38 cells were employed to investigate the cross-
talk between hypoxia and inflammation in colon cancer. The response to hypoxia in 
MC-38 cells is mediated by HIF-1. Consistently, HIF-1 protein and its classical 
target genes (Glut1, Ca9 and Phd3) were strongly induced upon hypoxic exposure of 
MC-38 cells.  
It was shown before, that the germ-free rats developed fewer and smaller chemically-
induced tumours compared to animals carrying regular gut microflora, suggesting a 
role of commensal microorganisms in colorectal carcinogenesis (253). The most 
common colonic bacteria are Gram-negative species whose outer membrane 
component lipopolysaccharide (LPS) is recognized by TLR4 (254). TLR4 knock-out 
mice were protected from tumours in a model of AOM/DSS-induced colon 
carcinogenesis, indicating a role of TLR4 signalling in CRC (255). Importantly, 
components of LPS signalling, TLR4 receptor and adapter MyD88, were shown to be 
overexpressed in tumour cells compared to normal and adenomatous epithelium in 
sporadic human colon cancers, and expression of TLR4 and MyD88 was associated 
with poor patient prognosis (256). Similarly, majority of colitis-associated cancers 
(CACs) were shown to display high expression levels of epithelial TLR4 (257), further 
underscoring the importance of TLR4 signalling in colon cancer cells. Therefore, in 
the current work, LPS was applied as a stimulus of inflammatory response of colon 
cancer cells.  
MC-38 cells displayd robust response of the transcription factor NF-B to 
proinflammatory treatment with LPS. The strong response of MC-38 cells to LPS was 
evidenced by nuclear translocation of NF-B upon exposure to proinflammatory 
stimulation. In addition, classical NF-B target gene (Tnfa, Il6 and Cox2) expression 
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was upregulated under the same conditions, confirming NF-B activation in MC-38 
cells subjected to treatment with LPS. MC-38 cells represent a suitable model to 
study the interplay between hypoxia and inflammation in this cancer type.  
It has been previously shown, that exposure to hypoxia may activate NF-B (262, 
274-276). Although MC-38 cells respond to hypoxia by upregulating the HIF pathway, 
hypoxic treatment does not lead to an increase in NF-B activation. No nuclear 
accumulation of NF-B was observed in MC-38 cells exposed to hypoxia. 
Consistently, hypoxic exposure did not alter the mRNA levels of classical NF-B 
target genes Tnfa, Il6 and Cox2. Hypoxia-mediated NF-B activation does not occur 
in the MC-38 colon cancer cells and these results support the notion that increased 
activity of NF-B in hypoxic conditions is not a ubiquitous phenomenon. 
One of the levels of the putative cross-talk between hypoxic and inflammatory 
pathways is direct transcriptional regulation of HIF-1 mRNA by NF-B that has been 
evidenced in different cells, but mainly macrophages (263-268). Although in the 
current work HIF-1 mRNA was shown to be regulated by NF-B in mouse primary 
peritoneal macrophages, Hif1a gene is not a transcriptional target of NF-B in MC-38 
cells. Neither the transcript, nor the protein levels of HIF-1 were affected by 
proinflammatory treatment of those cells. Consistently, expression of the classical 
HIF target genes Glut1, Ca9 and Phd3 was unaltered over a time-course of 
proinflammatory LPS treatment in MC-38. In line with the findings in MC-38 cells, in a 
panel of human colon cancer cell lines, the treatment with LPS did not affect the 
levels of HIF-1 mRNA, suggesting that this observation may be characteristic for 
colorectal carcinoma cells.  
Aiming at elucidating the mechanism responsible for lack of HIF-1 response to NF-
B activation in MC-38 cells, the possible methylation of B site in Hif1a promoter 
was addressed. Previous reports showed that HIF-1 may upregulate its own 
expression in hypoxic colon cancer cells if the HRE in its gene is unmethylated (313). 
Moreover, it was evidenced before, that the methylation of B sites may impair NF-
B binding (311, 312). To investigate the involvement of DNA methylation in the 
regulation of NF-B-mediated Hif1a induction, MC-38 cells were exposed to 
demethylating agent 5-aza-2´-deoxycytidine (5-aza-2`-dC). 5-aza-2`-dC pretreatment 
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in MC-38 cells did not result in an increase in HIF-1 mRNA levels after 
proinflammatory stimulation with LPS, despite induction of amphiregulin (AREG) 
mRNA levels, whose expression was previously shown to be regulated by 
methylation (314) and served here as a positive control of the DNA demethylation. 
Therefore, methylation of B site could not explain the lack of transcriptional 
activation of Hif1a gene by NF-B in MC-38 cells. Other unknown factors must 
therefore be responsible for conferring the cell-type specificity of transcriptional HIF-
1 response following proinflammatory treatment.  
Basal activity of NF-B pathway was shown to be required for HIF-1 response in 
hypoxic bone marrow-derived macrophages (BMDMs) as well as in livers and brains 
of mice (263). However, knock-down of p65/RelA neither resulted in alterations in 
HIF-1 mRNA levels, nor influenced HIF-1 protein accumulation or the response of 
its classical target genes (Glut1, Ca9 and Phd3) in hypoxia. HIF-1 pathway 
activation in hypoxic MC-38 cell is independent of basal NF-B activity. 
To investigate whether basal activity of HIF-1 affects NF-B signalling in MC-38 
cells,  the levels of p65/RelA mRNA and protein were tested in MC-38 stably 
expressing shRNA against HIF-1The levels of p65/RelA were not altered in HIF-1 
knock-down compared to control cells. This result was further confirmed by the lack 
of influence of basal HIF-1 expression on the nuclear translocation of NF-B or 
induction of well known NF-B target genes (Tnfa and Il6) after treatment with LPS in 
MC-38 cells. Basal HIF-1 expression is therefore irrelevant for the NF-B 
expression levels as well as for its activity following LPS treatment in MC-38 cells. 
As another level of possible interactions between hypoxia and inflammation, the 
effect of combined simultaneous response was analysed. RNA deep sequencing 
analysis of the HIF-1 and/or p65/RelA-dependent gene regulation in combination 
with different oxygen and/or LPS treatment conditions, revealed surprisingly 
prominent levels of reciprocal dependence between both pathways. Almost two thirds 
of hypoxia-induced genes were influenced by expression of both, HIF-1 and NF-B, 
whereas out of LPS-stimulated genes, regulation of about 12% was affected by 
expression of both transcription factors. Furthermore, the number of genes 
upregulated by the treatment with LPS in hypoxia was reduced by about 50% 
compared to proinflammatory stimulation under normal oxygen conditions. 
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Importantly, the lack of HIF-1 led to increased LPS-stimulated expression of several 
known NF-B target genes. These findings were independently confirmed for CCL20, 
CXCL5, CSF2 and TNF-transcript levels.  
The following validation experiments revealed inhibition of the LPS-stimulated 
decrease in IB levels following the MC-38 cells treatment in hypoxic compared to 
normoxic conditions. As a result, nuclear p65/RelA translocation in hypoxia was 
attenuated and this observation at least in part explains the inhibitory effect of 
hypoxia on the response to LPS. However, nuclear translocation of p65/RelA in 
response to LPS treatment was comparably affected by hypoxia in control and HIF-
1 knock-down cells. Therefore, further mechanistic insight into the role of HIF-1 in 
expression of Ccl20, Cxcl5, Csf2 and Tnfa is required. An indirect mechanism (such 
as induction of microRNA(s) targeting those genes) should be considered, since the 
genome-wide analysis of HIF binding loci excluded transcriptional inhibition mediated 
by HIF association to DNA (105).    
Hypoxia exerted inhibitory effects on the response of colon cancer cells to LPS 
treatment and HIF-1 itself had a negative effect on the expression of several 
strongly induced known NF-B target genes. It was shown previously that HIF-1 has 
a protective role in mouse model of colitis, preserving the barrier function of affected 
epithelia (260). Current work shows that HIF-1 inhibits the expression of a set of 
important inflammatory mediators in response to LPS treatment in colon cancer cells, 
indicating the possible existence of another mode of HIF-1-mediatied negative 
regulation of inflammation by modulating the recruitment and activation of leucocytes 
in CRC.   
Chronic intestinal inflammation is clearly associated with increased risk of 
development of CRC in humans (208, 209). Importantly, huge number of data on the 
possible use of nonsteroidal antiinflammatory drugs (NSAIDs) for chemoprevention of 
cancers has accumulated since late 1980s. NSAIDs inhibit cyclooxygenase 2 (COX-
2) and therefore proinflammatory prostaglandin synthesis, and this is the most 
probable mechanism of their preventive action in cancer (318). Aspirin, which 
belongs to NSAIDs, has been independently by different investigators shown to 
reduce the risk of CRC (319, 320), further strongly supporting the importance of 
inflammation as a driving force of colonic carcinogenesis. In turn, animal experiments 
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contributed to the establishment of a role of permanently active NF-B in the 
intestinal epithelium as a critical inducer of spontaneous tumourigensis (207). Current 
work shows that hypoxia which is a  hallmark of virtually all solid tumours blunts the 
response of mouse colon adenocarcinoma MC-38 cells to proinflammatory treatment 
with LPS, which induces cancer cell signalling suggested before to be associated 
with worse CRC patient survival (256). The membrane-permeable 
dimethyloxalylglycine (DMOG) mimics hypoxia by inhibiting PHD enzymes competing 
with one of their substrate -ketoglutarate (321). Interestingly, the treatment with 
DMOG was previously shown to suppress LPS-induced expression of cytokines in 
Raw264.7 macrophages (278). Our results support previously published data and 
suggest that the use of PHD enzyme inhibitors, such as DMOG, could be potentially 
beneficial in colorectal cancer patient treatment. 
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